Novel azabicyclohexane derivatives
New forms of azabicyclohexane derivatives, specifically solvates, address the challenge of emerging viral infections by enhancing antiviral activity and stability, offering improved therapeutic options for viral diseases like SARS-CoV2.
Patent Information
- Application Number
- PCT/RU2024/000158
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-21
AI Technical Summary
Current antiviral agents face challenges in effectively addressing emerging viral infections, particularly due to the rapid emergence of new viral diseases like SARS-CoV2, where existing therapies lack specificity and are hindered by high variability, necessitating the development of new drugs with improved physicochemical and pharmacological properties.
Development of new forms of azabicyclohexane derivatives, including solvates, which exhibit enhanced antiviral activity and improved storage stability, reducing hygroscopicity and increasing bioavailability, thereby offering a broader spectrum of antiviral efficacy.
The new azabicyclohexane derivatives demonstrate improved antiviral activity, increased storage stability, and reduced hygroscopicity, expanding the arsenal of antiviral agents with enhanced physicochemical and technological properties, effectively addressing the limitations of existing therapies.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000006_0001 
Figure IMGF000021_0001
Abstract
Description
[0001] NEW DERIVATIVES OF AZABICYCLOHEXANE
[0002] FIELD OF TECHNOLOGY TO WHICH THE INVENTION RELATES
[0003] The invention relates to the field of medicine, pharmacology and the chemical pharmaceutical industry and represents new forms of azabicyclohexane derivatives, including solvates of (!R,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2B)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide, as well as pharmaceutical compositions and drugs including them, which exhibit prophylactic and / or therapeutic antiviral activity.
[0004] One of the most pressing issues in modern medicine is the fight against viral infections. According to the World Health Organization (WHO), new infectious viral diseases are emerging at an alarming rate, with about 40 new infectious viral diseases having been discovered since the 1970s. Some of the most dangerous of the new emerging viruses include: severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002-2003, influenza (swine flu) A / H1N1 in 2009, Middle East respiratory syndrome coronavirus (MERS) in 2012, the Ebola virus disease epidemic in 2013-2015, the Zika virus pandemic in 2016-2017, and now SARS-CoV2, which has caused the COVID-19 pandemic. In addition to these newly identified pathogens, previously recognized viral infections, including pandemic influenza, yellow fever, measles, and others, continue to pose a threat due to the emergence of new epidemics (David A. Schwartz.Prioritizing the Continuing Global Challenges to Emerging and Reemerging Viral Infections / / Front.Virol.- 2021).
[0005] Phylogenetic analysis revealed that some single-stranded (+)RNA viruses can be assigned to a picornavirus-like supercluster, which includes viruses belonging to the Picomaviridae, Caliciviridae, and Coronaviridae families. A common feature of the picornavirus-like supercluster viruses is that they utilize 3C or 3C-like protease (3Cpro or 3C pro, respectively) in their metabolism. Conserved sites of 3Cpro or 3C pro may serve as attractive targets for the development of broad-spectrum antiviral drugs for viruses in the picornavirus-like supercluster. (Yunjeong Kim et al. Broad-Spectrum Antivirals against 3C or ЗС-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses / / J Virol. - 2012, - 86(21), p. 11754-11762). The SARS-CoV2 virus was identified as the causative agent of COVID-19, a severe viral infectious disease accompanied by acute respiratory distress.The coronavirus pandemic started on a global scale in December 2019. According to statistics, hundreds of thousands of cases and thousands of deaths are registered daily. As of October 11, 2021, the number of cases is 251 million, and deaths have crossed the 5 million mark. Since the beginning of the global pandemic, severe damage has been inflicted on both global human health and the global economy. The pandemic has served as a challenge to modern medicine, creating an urgent need to develop effective strategies for the prevention and treatment of viral diseases, as well as to create government stockpiles of targeted drugs. The lack of specific therapy against the new virus and its high variability require the creation of new drugs.
[0006] One of the promising ways to block the SARS-CoV2 virus is to inhibit the SARS-CoV2 protease, also called 3C-like protease (3CL or 3CLpro). Inhibition of 3CL protease prevents viral replication. An azabicyclohexane derivative, namely (lR,2S,5S)-N-[(lS)-l-pHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, which is characterized by the formula (V), inhibits the activity of the cysteine residue in the protease at the proteolysis stage. 3C pro is responsible for the process of cleaving the lipoproteins of the virus, which contain 3C pro itself, Pb pro (papain-like protease) and 14 other proteins. The molecule has shown high antiviral activity in preclinical studies on a model of SARS-CoV-2 adapted to mice.In addition, it is known from the prior art that (1P,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide can exhibit the ability to inhibit a wide range of 3C-like proteases not only of SARS-CoV-2, which emphasizes the possibility of use for others.
[0007] Compound of formula (V) When developing medicinal products, it is important that the substance, which is the active agent, is in a form with satisfactory physicochemical and technological properties, while exhibiting its pharmacological activity. The substance, which is the active agent, pharmaceutical compositions and medicinal products including it, must have the ability to be effectively stored under a wide variety of conditions for significant periods of time, without exhibiting significant changes in the physicochemical properties of the active agent (for example, its chemical composition, hygroscopicity, solubility, flowability).
[0008] The discovery of new forms of active agent opens up opportunities to improve the profile of the physicochemical, technological and pharmacological characteristics of a pharmaceutical product (medicinal product). This expands the range of active agents that a drug developer has at his disposal when developing a new drug with improved characteristics.
[0009] Thus, there is currently a continuing need to develop other, improved forms of antiviral agents.
[0010] Different solid forms of the same substance may have different properties, such as solubility, hygroscopicity, stability, bioavailability, flowability, compressibility, electrification, etc. These properties are carefully studied and taken into account when preparing drugs. In particular, hygroscopicity affects the stability of the drug, and poor flowability and compressibility indicators make it difficult to obtain solid drugs.
[0011] The variety of solid forms of active agents includes, but is not limited to, crystalline, amorphous forms; co-crystals; solvates, including hydrates, salts, solvates of salts, including hydrates of salts (these forms can be either in crystalline or amorphous form, or in the form of a mixture of crystalline and amorphous form).
[0012] In recent years, scientists have devoted much time to studying solvated forms of active agents due to their great diversity and differences in physicochemical properties. Sometimes, solvated active agents are preferable for drug development. However, substances containing solvated substances are usually difficult to obtain due to their possible metastable state, while they often have other disadvantages such as increased electrostaticity, particle agglomeration, and poor powder flowability. Some solvated substances tend to undergo spontaneous desolvation and transform into other crystalline or amorphous forms, which leads to changes in the pharmacological and physicochemical properties of the drug, both for the better and for the worse (Ngilirabanga J. B., Samsodien H. Pharmaceutical co-crystal: An alternative strategy for enhanced physicochemical properties and drug synergy / / Nano Select. - 2021. -V. 2. - No. 3. - P. 512-526).For example, the prior art describes a case of the formation of a hydrated form of carbamazepine, accompanied by a deterioration in the biological activity of the substance (Pinto M. AL et al. Thermoanalytical studies of carbamazepine: hydration / dehydration, thermal decomposition, and solid phase transitions / / Brazilian Journal of Pharmaceutical Sciences. - 2014. - V. 50. - P. 877-884.).
[0013] Transformation of an active substance into a certain form is a means of changing, and sometimes optimizing its physicochemical properties. However, it is known that even a minor change in the molecule of a pharmaceutical active substance (for example, obtaining its salt, base, acid, ester, etc.) with full preservation of its part responsible for the pharmacological action, can significantly affect its therapeutic effect. Even a minor change in the structure of a pharmaceutical active ingredient can increase or decrease its therapeutic activity and stability, eliminate or, conversely, lead to the appearance of an undesirable side effect, and also seriously affect its pharmacokinetics (A.I. Tikhonov, E.E. Bogutskaya, T.G. Yarnykh, A.M. Kotenko. Practical training in biopharmaceuticals / / Kharkov. Publishing House of the National Pharmaceutical University "Golden Pages". - 2003. - P. 95. p. 53).
[0014] Thus, when developing drugs, it is necessary to establish and take into account the characteristics of solid forms and various modifications of active agents. They must, in particular, have the ability to dissolve well and be stored for long periods of time without showing significant changes in physicochemical and pharmacological properties.
[0015] The prior art discloses a solvated form of an azabicyclohexane derivative with methyl tert-butyl ether, namely, (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide. The prior art (Owen DR et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 / / Science. - 2021. - V. 374. - No. 6575. - Pp. 1586-1593; WO2021250648) describes a method for producing and the structure of a crystalline form of methyl tert-butyl ether solvate (N,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, which was taken as a prototype.All methods described in the prior art for obtaining methyl tert-butyl ether solvate of (^,28,58)--[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide are reduced to recrystallization of the reaction mixture concentrate after the extraction step. Both sources (Owen DR et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 / / Science. - 2021. - V. 374. - No. 6575. - Pp. 1586-1593; WO202 1250648) cited above characterize the absolutely identical crystal structure of the obtained solvates of (lR,2S,5S)-N-[(lS)-l-nnaHO-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide with methyl tert-butyl ether. Below is a table and diffraction pattern from the article (Owen DR et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-.
[0016] 19 / / Science. - 2021. - V. 374. - No. 6575. - P. 1586-1593) with a listing of peaks at angles
[0017] 20 in the powder X-ray diffraction pattern, which is identical to the data specified in the international application (WO2021250648). Counts - intensity.
[0018] ***2Theta - 2 theta.
[0019] ****Angle (°2-theta) + / - 0.2° 2-Theta - Angle (°2-theta) + / - 0.2° 2-Theta. *****Relative Intensity (%) - Relative intensity (%).
[0020] DISCLOSURE OF THE ESSENCE OF THE INVENTION
[0021] Thus, the objective of the present invention was to develop new improved forms of azabicyclohexane derivatives, including crystalline and amorphous forms of solvates of azabicyclohexane derivatives.
[0022] As a result of long-term experimentation, the authors of the present invention have obtained and studied new forms of azabicyclohexane derivatives, in particular, pharmaceutically acceptable solvates of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide, which have improved antiviral activity, as well as increased effectiveness in relation to the prevention, including post-exposure, of viral infections. Studies of the properties of the new forms of azabicyclohexane derivatives made it possible to establish their improved physicochemical and pharmacological properties.
[0023] Thus, the technical results of the present invention are: improved antiviral activity of the new forms of azabicyclohexane derivatives according to the present invention;
[0024] - improving the physicochemical properties (including improving solubility) of new forms of azabicyclohexane derivatives according to the present invention, as well as pharmaceutical compositions and medicines that contain them;
[0025] - expansion of the arsenal of antiviral agents with new pharmacological, physicochemical and technological properties.
[0026] The inventors also unexpectedly discovered that solvated forms of the azabicyclohexane derivatives of the present invention, including (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, including in crystalline and amorphous forms according to the present invention, reduce the severity of the clinical course of viral infection, exhibit improved antiviral activity, physicochemical and technological properties, in particular, increased stability during storage, reduced hygroscopicity of substances (by about 2-4 times), compared to known forms (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0027] Below are definitions of terms that are used in the description of the present invention.
[0028] Unless otherwise specified, all technical and specialized terms used in this context have their generally accepted meaning in the art.
[0029] In the context of the present invention, the term "excipient" characterizes substances of inorganic or organic origin used in the process of production, manufacture of medicines or pharmaceutical compositions to impart to them the necessary physicochemical properties.
[0030] The term "pharmaceutical composition" in the context of the present invention means a composition comprising a therapeutically active agent or a combination of active agents and, if necessary, at least one of pharmaceutically acceptable and pharmacologically compatible excipients. The pharmaceutical compositions of the present invention include, inter alia, substances containing an active agent or a combination of active agents.
[0031] The term "pharmaceutically acceptable" in the context of the present invention means that the substance or composition to which the term is applied must be chemically and / or toxicologically compatible with the other ingredients of the pharmaceutical composition or drug and safe for the person being treated with the substance or composition.
[0032] "Pharmaceutically acceptable salt" in the context of the present invention means relatively safe and non-toxic organic and inorganic salts of the acids and bases claimed in the present invention.
[0033] The term "medicinal product" in the context of the present invention characterizes substances or a mixture of substances of synthetic or natural origin that come into contact with the human or animal body, penetrate into the organs and tissues of the human or animal body, and are used for the prevention or treatment of diseases. Medicinal products include medicinal preparations in the form of finished dosage forms that include an active agent and at least one excipient, intended for administration into the animal or human body by various methods, such as, but not limited to, orally, sublingually, locally, including, but not limited to, ocular, nasal administration, etc., rectally, parenterally (intradermally, subcutaneously, intramuscularly, intravenously, intraarterially, into cavities).Suitable standard forms of administration include (without limitation) oral forms: tablets, capsules, pellets, granules, powders, solutions, solutions for spraying into the oral and nasal cavity, syrups, suspensions, etc., oral: solutions, suspensions, emulsions, concentrates for the preparation of injection and infusion dosage forms, aerosols and powders for inhalation administration, powders and lyophilisates for the preparation of injection and infusion dosage forms; rectal: suppositories, capsules, etc.; eye drops.
[0034] The amount of active agent administered (dosage) will depend on the subject to be treated (individual patient characteristics, but not limited to age and body weight), the severity of the disorder or condition of the subject. An effective dosage of the active agent of the present invention is in the range of about 30 to 7000 mg per day, without causing any adverse side effects. If necessary, doses are usually divided into several smaller doses for administration throughout the day.
[0035] The expression “is in solid form” in the context of the present invention characterizes pharmaceutical substances, pharmaceutical compositions and medicinal products of a solid, dense or viscous consistency, wherein the particles actively interact with each other, allowing the substance to maintain its size and shape.
[0036] The term "...which is / are essentially a solvated form..." in the context of the present invention, characterizes a composition that has less than about 25.00 wt.% of the total composition of the unsolvated form of the azabicyclohexane derivatives of the present invention (in particular, less than 20.00 wt.%, less than 15.00 wt.%, less than 10.00 wt.%, less than 5.00 wt.%, less than 2.00 wt.%, less than 1.00 wt.%, or does not contain the unsolvated form at all). In this case, the total content of impurities in the composition complies with the regulatory documentation.
[0037] The term “including”, “comprising”, “comprises” in the context of the present invention means that the said pharmaceutical substances, pharmaceutical compositions and medicinal products include the listed components, but do not exclude the inclusion of other components.
[0038] The term "effective amount" in the context of the present invention means an amount of a substance (as well as a combination of substances) that, when administered to a subject for the treatment or prevention of a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient for such treatment and / or prevention to have an effect on the disease, disorder or symptom. "Effective amount" is determined depending on the disease, disorder and / or symptoms of the disease or disorder, the severity of the disease, disorder and / or symptoms of the disease or disorder, the clinical picture and general health of the patient, as well as the age and / or weight of the subject who requires such treatment and / or prevention.
[0039] The term "powder" as used herein means a state of matter in which the solid substance or substances that comprise it are in a free dispersion system without a dispersion medium with a dispersion phase in the form of solid particles of various shapes.
[0040] The terms “approximately” and “about” used in the text mean approximately plus or minus ten percent of the specified value.
[0041] The term "solvate" in the context of the present invention characterizes a stable structure of a fixed composition, which simultaneously includes molecules of an active agent and a solvent, which are firmly bound to each other by electrostatic interaction. Solvates can also be divided into stoichiometric and non-stoichiometric (Griesser UJ The importance of solvates / / Polymorphism: In the pharmaceutical industry. - 2006. - P. 211-233). Stoichiometric solvates have a fixed ratio of active substance and solvent in their crystal lattice, whereas non-stoichiometric solvates can include various ratios of the amounts of active substance and solvent.
[0042] The term "impurities" in the context of the present invention is any component of a substance, pharmaceutical composition and / or medicinal product that is not an active agent or excipient. The quality indicator of a substance, pharmaceutical composition and / or medicinal product characterizes the content of impurities in the substance, pharmaceutical composition and / or medicinal product, including residual impurities that entered the substance, pharmaceutical composition and / or medicinal product during the synthesis of the active agent(s) (including related impurities), during the production of the substance, pharmaceutical composition / medicinal product (process impurities), as well as those formed during the degradation of the components of the substance, pharmaceutical composition and / or medicinal product during storage, and is expressed as a percentage. The source of impurities may be reagents, catalysts, process equipment used in the synthesis of the starting materials,residues of filter materials, insufficiently purified starting materials used for the synthesis of components of a pharmaceutical composition and / or a medicinal product and the production of a substance, pharmaceutical compositions / medicines. "Structural analogues" (or chemical analogues, or analogs, or structurally related compounds, or derivatives) in the context of the present invention characterize chemical compounds that differ from the target compound by one or more atoms, for example, without limitation, isotopes of atoms, functional groups such as alkyl (saturated or unsaturated), cycloalkyl, heterocyclic, aryl (substituted or unsubstituted), alcohol, alkoxy, carbonyl (aldehyde or ketone), carboxyl, ester, amino group (including substituted), nitro group, nitroso group, nitrile, hydrazine, amide, thiol, sulfide, disulfide, sulfoxide, sulfone,halogen atoms; any of the functional groups may be replaced by another functional group or atom; isomers of the chemical compound, including structural and spatial isomers (namely, geometric, such as cis / trans isomers, optical, such as R / S isomers, D / L isomers, enantiomers, diastereomers, dynamic, such as tautomers, conformational); various solid forms of the chemical compound, namely, salts (of organic and inorganic acids and bases), complexes, amorphous forms, crystalline forms (namely, all polymorphic forms), semi-crystalline forms, solvates, including hydrates, clathrates, co-crystals, prodrugs, metabolites.
[0043] The term "alkyl" in the context of the present invention refers to a saturated aliphatic hydrocarbon radical comprising straight chain and branched chain groups of 1-20 carbon atoms, preferably 1-12 carbon atoms, more preferably 1-8 carbon atoms, or 1-7 carbon atoms, or 1-6 carbon atoms, or 1-5 carbon atoms. "Lower alkyl" refers specifically to an alkyl group with 1-4 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, 2-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, and the like.
[0044] The term "cycloalkyl" refers to a 3- to 10-membered carbon monocyclic ring, a 4-membered / 6-membered, 5-membered / 6-membered, or 6-membered / 6-membered carbon fused bicyclic ring, or a polycyclic fused group (a "fused" ring system means that each ring in the system shares an adjacent pair of carbon atoms with every other ring in the system), wherein one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. Examples, but not limited to, of cycloalkyl groups include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, adamantane, cycloheptane, cycloheptatriene, etc. The term "aryl" in the context of the present invention refers to carbon monocyclic groups or polycyclic groups with fused rings of 6 to 12 carbon atoms having a fully conjugated π-electron system.Examples, without limitation, of aryl groups include phenyl, naphthalenyl, and anthracenyl.
[0045] The term "heterocycle" or "heteroaryl" in the context of the present invention refers in particular to a monocyclic or condensed ring group of 5 to 12 ring atoms, more preferably 4 to 10 ring atoms, containing one, two, three, four or five ring heteroatoms selected from N, O and S, the remaining ring atoms being C, and, in addition, having a completely conjugated π-electron system.Examples, but not limited to, of unsubstituted heteroaryl groups include pyrrole (pyrrolyl), furan (furanyl), thiophene (thiophenyl), imidazole (imidazolyl), oxazole (oxazolyl), isoxazole (isoxazolyl), thiazole (thiazolyl), 1,2,3-triazole (1,2,3-triazolyl), 1,3,4-triazole (1,3,4-triazolyl), 1-oxa-2,3-diazole (1-oxa-2,3-diazolyl), 1-oxa-2,4-diazole (1-oxa-2,4-diazolyl), 1-oxa-2,5-diazole (1-oxa-2,5-diazolyl), 1-oxa-3, 4-diazole (1-oxa-3,4-diazolyl), 1-thia-2, 3-diazole (1-thia-2,3-diazolyl), 1-thia-2, 4-diazole (1-thia-2,4-diazolyl), 1-thia-2, 5-diazole (1-thia-2,5-diazolyl), 1-thia-3, 4-diazole (1-thia-3,4-diazolyl), isothiazole (isothiazolyl), pyrazole (pyrazolyl), pyrazine (pyrazinyl), pyridine (pyridinyl), pyrimidine (pyrimidinyl), pyridazine (pyridazinyl), quinoline (quinolinyl), isoquinoline (isoquinolinyl), purine (purinyl), tetrazole (tetrazolyl), triazine (triazinyl) and carbazole (carbazolyl).
[0046] Examples of fused ring heterocycles include, but are not limited to: benzofuran (benzofuranyl), benzothiophene (benzothiophenyl), indole (indolyl), benzimidazole (benzimidacholyl), indazole (indazolyl), benzotriazole (benzotriazolyl), pyrrolo[2,3-b]pyridine (pyrrolo[2,3-b]pyridinyl), pyrrolo[2,3-c]pyridine (pyrrolo[2,3-c]pyridinyl), pyrrolo[3,2-c]pyridine (pyrrolo[3,2-c]pyridinyl), pyrrolo[3,2-b]pyridine (pyrrolo[3,2-b]pyridinyl), imidazo[4,5-b]pyridine (imidazo[4,5-b]pyridinyl), imidazo[4,5-c]pyridine (imidazo[4,5-c]pyridinyl), pyrazolo[4,3-b]pyridine (pyrazolo[4,3-<1]pyridinyl), pyrazolo[4,3-c]pyridine (pyrazolo[4,3-c]pyridinyl), pyrazolo[3,4-c]pyridine (pyrazolo[3,4-c]pyridinyl), pyrazolo[3,4-b]pyridine (pyrazolo[3,4-b]pyridinyl), isoindole (isoindolyl), indazole (indazolyl), purine (purinyl), indolizine (indolizinyl), imidazo[1,2-a]pyridine (imidazo[1,2-a]pyridinyl), pyrazolo[1,5-a]pyridine (pyrazolo[1,5-a]pyridinyl), pyrrolo[1,2-b]pyridazine (pyrrolo[1,2- b]pyridazinyl), imidazo[1,2-c]pyrimidine (imidazo[1,2-c]pyrimidinyl), quinoline (quinolinyl), isoquinoline (isoquinolinyl), cinnoline (cinnolinyl), quinazolin (quinazolinyl), quinoxaline (quinoxalinyl), phthalazine (phthalazinyl), 1,6-naphthyridine (1,6-naphthyridinyl), 1,7-naphthyridine (1,7-naphthyridinyl), 1,8-naphthyridine (1,8-naphthyridinyl), 1,5-naphthyridine (1,5-naphthyridinyl), 2,6-naphthyridine (2,6-naphthyridinyl), 2,7-naphthyridine (2,7-naphthyridinyl), pyrido[3,2-<1]pyrimidine (pyrido[3,2-<1]pyrimidinyl), pyrido[4,3-c!]pyrimidine (pyrido[4,3-<1]pyrimidinyl), pyrido[3,4-<1] pyrimidine (pyrido[3,4- c!]pyrimidinyl), pyrido[2,3-b]pyrimidine (pyrido[2,3-c!]pyrimidinyl), pyrido[2,3- b]pyrazine (pyrido[2,3-b]pyrazinyl), pyrido[3,4-b]pyrazine (pyrido[3,4-b]pyrazinyl), pyrimido[5,4-<1]pyrimidine (pyrimido[5,4-b]pyrimidinyl), pyrazino[2,3-b]pyrazine (pyrazino[2,3-b]pyrazinyl), pyrimido[4,5-b]pyrimidine (pyrimido[4,5-<1]pyrimidinyl).,
[0047] Also, "heterocycle" in the context of the present invention may refer to a monocyclic group or a fused ring group having in the ring(s) from 3 to 12 ring atoms, more preferably from 4 to 10 ring atoms, in which from 1 to 5 ring atoms are heteroatoms selected from N, O and S(O)n (where n is 0, 1 or 2), and the remaining ring atoms are C. The rings may also have one or more double bonds. However, the rings may not have a completely conjugated π-electron system. Examples of heterocycles also include, but are not limited to: oxirane (oxiranyl), thiaran (thiaranyl), aziridine (aziridinyl), oxetane (oxetanyl), thiatan (thiatanyl), azetidine (azetidinyl), tetrahydrofuran (tetrahydrofuranyl), tetrahydrothiophene (tetrahydrothiophenyl), pyrrolidine (pyrrolidinyl), tetrahydropyran (tetrahydropyranyl), tetrahydrothiopyran (tetrahydrothiopyranyl), piperidine (piperidinyl), 1,4-dioxane (1,4-dioxanyl), 1,4-oxathiane (1,4-oxathianyl),morpholine (morpholinyl), 1,4-dithianyl (1,4-dithianyl), piperazine (piperazinil), 1,4-azathianyl (1,4-azathianil), oxepan (oxepanil), tiepane (tiepanil), azepane (azepanil), 1,4-dioxepane (1,4-dioxepanyl), 1,4-oxathiepane (1,4-oxathiepanyl), 1,4-oxaazepane (1,4-oxaazepanyl), 1,4-dithiepane (1,4-dithiepanyl), 1,4-thiazepane (1,4-thiezapanil), 1,4-diazepane (1,4-diazepanyl), 3,4-dihydro-2H-pyran (3,4-dihydro-2H- piranil), 5,6-dihydro-2H-pyran (5,6-dihydro-2H-pyranyl), 2H-pyran (2H-pyranyl), 1,2,3,4-tetrahydropyridine (1,2,3,4-tetrahydropyridinyl), 1,2,5,6-tetrahydropyridine (1,2,5,6-tetrahydropyridine) .,
[0048] In this case, the heterocyl group is optionally substituted by one, two or three substituents selected (independently of each other) from the group, not limited to the specified, C1-C7 alkyl, including branched; halogen, for example, not limited to the specified, chlorine, fluorine, bromine, iodine; hydroxy group, phenyl, benzyl, aryl, amino, oxo or cyano groups.
[0049] "Hydroxy" in the context of the present invention refers to the group -OH. "Alkoxy" in the context of the present invention refers to both -O-(Ci-Cs- alkyl) and -O-(unsubstituted cycloalkyl) groups. In particular, but not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyl oxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0050] "Cyano" in the context of the present invention refers to the -ON group.
[0051] "Amino" in the context of the present invention refers to the group -NH2.
[0052] The azabicyclohexane derivatives of the present invention, novel forms of the azabicyclohexane derivatives, in particular solvated forms of the azabicyclohexane derivatives of the present invention, or structural analogs thereof can be administered in the form of a prodrug. The prodrug can include a covalently bonded carrier that releases the active parent drug when administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds such that the modifications are cleaved, either during routine manipulation or in vivo, to the parent compounds. Prodrugs include, for example, compounds in which a hydroxyl group is bonded to any group that, when administered to a subject, cleaves to form a free hydroxyl group. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol functional groups in the compounds.Typical prodrugs form an active metabolite by conversion of the prodrug by hydrolytic enzymes, hydrolysis of amides, lactams, peptides, carboxylic acid esters, epoxides, or cleavage of inorganic acid esters.
[0053] The term “physicochemical properties of substances” in the context of the present invention characterizes the density, shape, size and nature of the surface of particles, the specific surface of particles, the forces of adhesion (sticking together on the surface) and cohesion (sticking together of particles inside the body), surface activity, melting point, solubility, hygroscopicity, stability, reactivity of substances, etc.
[0054] The term “technological properties of substances” in the context of the present invention characterizes the bulk density, degree of compaction, flowability, moisture, fractional composition, dispersion, porosity, compressibility of substances, etc.
[0055] The term "crystalline form" in the context of the present invention defines a spatially homogeneous, equilibrium state of a substance characterized by a certain elemental composition and structure. The crystalline phase can be represented by a set of crystals of different sizes, but belonging to one crystalline form. Substances of a crystalline form give precise diffraction maxima on a powder diffraction pattern, which appear near specific angles consistent with the interplanar distances of the crystal lattice.
[0056] The term "polymorphic form" in the context of the present invention means a specific crystalline form of one chemical compound that differs from other forms of the same chemical compound in physicochemical properties. Each polymorphic form is characterized by certain parameters of the unit crystallographic cell and symmetry group, as well as a diffraction profile. Thus, polymorphic forms of a chemical compound according to the present invention are different crystalline forms of a certain compound that have the same chemical formula, but each polymorphic form may have physicochemical properties that differ from other polymorphic forms. In particular, physicochemical properties such as solubility profile, hygroscopicity, particle shape, stability, bioavailability, electrification, flowability, compressibility, caking, etc. may differ.
[0057] The term "powder X-ray diffraction" in the context of the present invention characterizes an analytical method that allows qualitatively and quantitatively determining various forms of substances in their mixture based on the analysis of the diffraction pattern created by irradiating the sample under study with X-rays. Crystalline substances give precise diffraction maxima that appear near specific angles consistent with the interplanar distances of the crystal lattice. In contrast, amorphous substances do not have a long-range order and give a broadened peak in the form of a halo in the diffraction pattern. Powder X-ray diffraction is the most effective method for identifying various types of solid forms of a substance.
[0058] The term "2 theta value" or "20" refers to the position of the peak in the diffraction pattern of the sample under study and is a generally accepted unit along the abscissa axis in diffraction patterns. An X-ray beam falls on certain planes of crystal lattices at an angle of 0 and is reflected from them. In this case, at an angle of 0, the diffraction maximum for this type of planes is observed. The angle 20 is measured in degrees.
[0059] "Diffractogram" in the context of the present invention characterizes the dependence of the intensity of X-ray diffraction on the diffraction angle 20.
[0060] The term "elementary crystallographic cell" in the context of the present invention means a part of the crystal lattice, parallel transfers of which in three dimensions (translations) allow the entire crystal lattice to be constructed. The term "number of molecules (formula units) in the elementary crystallographic cell Z" is the minimum set of formula units (atoms or molecules) describing the chemical composition of the crystal and having a formal zero charge.
[0061] The parameters a, b, c, a (alpha), (beta), y (gamma) are the parameters of the unit cell characterizing the syngony and symmetry group of the crystal. The choice of edges a, b, c and the angles between them a (alpha), 0 (beta), y (gamma) can be arbitrary, provided that the edges a, b, c do not simultaneously lie in one plane and intersect at one point. However, it is generally accepted, but not mandatory, in crystallographic practice to choose the edges corresponding to the following arrangement: the angle a (alpha) is formed by the edges c and b, the angle 0 (beta) is formed by the edges a and c, the angle y (gamma) is formed by the edges a and b.
[0062] The term "singony" is a division of crystals based on the symmetry of their elementary crystallographic cell. The syngony is characterized by the relationships between the axes a, b, c and the angles a, 0, y of the cell. There are 7 crystallographic syngonies: cubic (in particular, a = b = c, a = 0 = y = 90°), tetragonal (in particular, a = b c, a = 0 = y = 90°), hexagonal (in particular, a = b = c, a = 0 = 90°, y = 120°), trigonal (in particular, a = b = c, a = 0 = 90°, y = 120°), rhombic (in particular, a b c, a = 0 = y = 90°), monoclinic (in particular, a b c, a = y = 90°, 0 90°), triclinic (in particular, a b c, a 0 y 90°). Being the largest classification division in crystal symmetry, each syngony includes several spatial symmetry groups.
[0063] The arrangement of atoms in the unit cell is specified by the lengths of the segments of the edges of the unit cell to the corresponding sides a, b, c. "Fractional coordinates of atoms" in the context of the present invention characterize the spatial arrangement of atoms in the unit cell, and are expressed along each of the axes x, y, z, as a fraction of the corresponding parameter of the unit cell a, b, c.
[0064] The term "space group" in the context of the present invention is a set of symmetry transformations of a crystal lattice that combine this lattice with itself. There are 230 different space symmetry groups in total. Of these, 32 groups are used in crystallography to describe symmetry, they are also called point symmetry groups.
[0065] The term "equivalent thermal parameters" is a measure of the displacement of an atom during thermal motion in a crystal. The terms "approximately" and "about" used in the text mean approximately plus or minus ten percent of the specified value.
[0066] The term "amorphous form" in the context of the present invention means a solid substance that does not have a distinguishable crystal lattice and in which there is no unlimitedly repeating ordering at large distances in the mutual arrangement of molecules in the substance, inherent in crystals. In particular, an amorphous form is one that is characterized by a diffuse halo and almost does not show sharp peaks in an X-ray diffraction pattern, but with certain changes, distinguishable diffuse maxima (peaks) can be revealed against the background of a diffuse halo.
[0067] The term "crystalline ( ,28,58)-T\[-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide" or "(lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- "(trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline form" in the context of the present invention characterizes the substance ((28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, which is essentially a crystalline phase obtained by methods known from the prior art, characterized by a specific X-ray powder diffraction pattern (WO2021250648, PFIZER, form 1; the main peaks in the powder diffraction pattern are recorded at the following angles 20, 0 (±0.20): 7.60, 15.70, 15.80, 18.30, 20.50, etc.).
[0068] The term "amorphous (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide" or "(lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1 ,0]hexane-2-carboxamide in amorphous form" in the context of the present invention characterizes the substance (1R,2S,5S)- N- [( 1 S)- 1 -cyano-2- [(38)-2-oxopyrrolidin-3 -yl]ethyl]-3 - [(2S)-3 ,3 -dimethyl-2- [(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, which is essentially an amorphous phase obtained by methods known from the prior art, characterized by the presence of diffuse halos without distinct peaks in the powder X-ray diffraction pattern (WO2021250648, PFIZER, form 5, a wide halo is recorded in the powder diffraction pattern in the region of angles 20 (± 2.00°): 8.00 - 25.00).
[0069] For the preparation of the azabicyclohexane derivatives of the present invention, novel forms of the azabicyclohexane derivatives, in particular solvated forms of the azabicyclohexane derivatives of the present invention, the following solvents, their deuterated derivatives or mixtures thereof known in the art can be used: alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, 2-butanol, isobutanol, tert-butanol, amyl alcohol and its isomers, cyclohexanol, benzyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, ketones such as acetone, butanone, methyl isobutyl ketone, 2-hexanone, cyclopentanone, cyclohexonone, ethers such as ethyl formate, methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, ethylene glycol diacetate, propylene glycol diacetate, glycerol triacetate, diethyl ether, diisopropyl ether, dibutyl ether, tetrahydrofuran, methyltetrahydrofuran, dioxane, anisole, methyl tert-butyl ether, ethyl tert-butyl ether,cyclopentyl methyl ether, dimethoxyethane, diethoxymethane, diglyme, lactones such as butyrolactone, valerolactone, hydrocarbons such as n-pentane, n-hexane, n-heptane, n-octane, cyclohexane, methylcyclohexane, benzene, toluene, xylenes, cumene, tetralin, limonene, turpentine, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethylene, cis-dichloroethylene, trans-dichloroethylene, 1,1,2-trichloroethylene, 1,1,1-trichloroethane, 1-chlorobutane, chlorobenzene, dichlorobenzene, aprotic polar solvents such as acetonitrile, propionitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethylolethylene urea, dimethylolpropylene urea, dimethyl sulfoxide, sulfolane, nitromethane, bifunctional solvents such as methoxyethanol, ethoxyethanol, 1-methoxypropan-2-ol, furfuryl alcohol, tetrahydrofurfuryl alcohol, ethyl lactate, protic solvents such as water, acids such as formic acid, acetic acid, propionic acid,trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, anhydrides such as acetic anhydride, ammonia, amines such as pyridine, thiethylamine, as well as supercritical fluids such as carbon dioxide, water, methane, ethane, propane, ethylene, propylene, methanol, ethanol, acetone, nitrogen oxides, sulfur oxide; or mixtures thereof.,
[0070] BRIEF DESCRIPTION OF DRAWINGS
[0071] The present invention is further illustrated by means of the figures: Fig. 1.1 - 1.5 show the DSC and TGA curves of the crystalline form of ethyl acetate (1.1), propyl acetate (1.2), butyl acetate (1.3), isobutyl acetate
[0072] (1.4), tetrahydrofuran (1.5) solvates of (lR,2S,5S)-N-[(lS)-l-4naHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0073] Fig. 2.1-2.5 show the diffraction patterns of ethyl acetate (2.1), propyl acetate (2.2), butyl acetate (2.3), isobutyl acetate (2.4), and tetrahydrofuran (2.5) solvates of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in amorphous form.
[0074] Fig. 3.1-3.5 show general types of formula units of elementary cells of ethyl acetate (3.1), propyl acetate (3.2), butyl acetate (3.3), isobutyl acetate
[0075] (3.4), tetrahydrofuran (3.5) solvates of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline form.
[0076] Fig. 4.1-4.5 show general types of diffraction patterns of crystalline forms of ethyl acetate (4.1), propyl acetate (4.2), butyl acetate (4.3), isobutyl acetate
[0077] (4.4), tetrahydrofuran (4.5) solvates of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide.
[0078] Figure 5 shows the virus titer in the lungs of groups of hamsters treated with the ethyl acetate solvate of ( 1 R,2S,5 S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1); butyl acetate solvate of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
[0079] (2); tetrahydrofuran solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
[0080] (3); isobutyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (4); propyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (5); acetone solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (6); dimethylformamide solvate (1 R,2S,5 S)-N-[(1 S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (7); dimethyl sulfoxide solvate of (lR,2S,5S)-N-[(lS)-l-UHaHo-2-[(3S)- 2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (8); (28,58)-M-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide with ethanolic solvate (9); (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)- 2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (10); (1^,28,58)-M-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1] diethyl ether solvate.0]hexane-2-carboxamide (I), methyl tert-butyl ether solvate (,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (16); microcrystalline cellulose (17).
[0081] Figure 6 shows the virus titer in the lungs of groups of hamsters treated with the ethanol solvate of (28,58)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (12); tetrahydrofuran solvate (lR,2S,5S)-N-{(l S)-l-unaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[1-(chlorodifluoroacetyl)-b-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (13), ethyl acetate solvate of (1R,2S,5S)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[M-(trifluoroacetyl)--seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (14), butyl acetate solvate (^,28.58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-
[0082] (trifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (15), methyl tert-butyl ether solvate of (lR,2S,5S)-N-[(lS)-l-IIHAHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (16); microcrystalline cellulose (17). EMBODIMENT OF THE INVENTION
[0083] The stated task is solved, and the stated technical results are achieved due to a new compound selected from a group including compounds characterized by Formula I, their stereoisomers and structural analogs:
[0084] Formula I wherein X is selected from the group consisting of ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, Ri and R.2 independently of one another are Ci-C7 alkyl, R3, R.4, Rs independently of one another are chlorine or fluorine, R6 is selected from the group consisting of Ci-Cs alkyl, including branched, Ci-Cs alkoxy, C3-C10 cycloalkyl, phenyl, aryl, 4-10-membered heterocycle optionally condensed with a 4-10-membered heterocycle, C4-C10 cycloalkyl or aryl, wherein said heterocycle contains 1-5 heteroatoms selected from -N, -S and -O, wherein Re is optionally substituted with C1-C7 alkyl, halogen, hydroxy group, phenyl, benzyl, aryl, amino, oxo or cyano groups, w = 0.5-5.0, n = 1.0-3.0, where n is an integer.
[0085] The stated task is solved, and the stated technical results are achieved due to a new compound selected from a group including compounds characterized by Formula II, their stereoisomers and structural analogs: where X is selected from the group consisting of ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, Ri and R.2 independently of one another are Ci-C7 alkyl, R3, Id, Rs independently of one another are chlorine or fluorine, Re is selected from the group consisting of Ci-Cs alkyl, including branched, Ci-Cs alkoxy, C3-C10 cycloalkyl, phenyl, aryl, a 4-10-membered heterocycle optionally condensed with a 4-10-membered heterocycle, C4-C10 cycloalkyl or aryl, wherein said heterocycle contains 1-5 heteroatoms selected from -N, -S and -O, wherein Re is optionally substituted with C1-C7 alkyl, halogen, hydroxy group, phenyl, benzyl, aryl, amino, oxo or cyano groups, m = 0.5-5.0, n = 1.0-3.0, where n is an integer.
[0086] The stated problem is solved and the claimed technical results are achieved due to a new compound selected from a group including compounds characterized by Formula II, where X is selected from a group including ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, Ri and R2 independently of one another are Ci-alkyl, R3, R4, Rs independently of one another are fluorine, R6 is tert-butyl, m = 0.5-3.0, n = 1.0.
[0087] The stated problem is solved, and the stated technical results are achieved by obtaining and using a new compound selected from a group including compounds characterized by Formula IV:
[0088] Formula IV where X is selected from the group consisting of ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, and w = 0.5-5.0.
[0089] One embodiment of the present invention is the ethyl acetate solvate of (1^28,58)-P-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; butyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; tetrahydrofuran solvate of (1 R,2S,5S)-N-[(1 S)- 1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; isobutyl acetate solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; ethanol solvate of (^,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; hydrate (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; diethyl ether solvate of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; dimethylformamide solvate of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; dimethyl sulfoxide solvate ( ,28,58)-M-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide or propyl acetate solvate (1R,2S,5S)-N-[(1S)-.
[0090] 1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0091] To determine the structure of the compounds within the framework of the present invention, methods of infrared spectroscopy, nuclear magnetic resonance spectroscopy, elemental analysis, structural studies and thermogravimetric methods were used, among other things. A portion of the experiments sufficient for analyzing the compounds according to the present invention are presented in the examples of the present invention.
[0092] The stated problem is solved, and the declared technical result is achieved by obtaining a crystalline form of ethyl acetate solvate (lR,2S,5S)-N-[(lS)-l-nHaHO-
[0093] 2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide in a ratio of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide to solvating solvent 1:1.
[0094] The stated problem is solved and the claimed technical result is achieved due to the crystalline form of ethyl acetate solvate (lR,2S,5S)-N-[(lS)-l-unaHO-2-[(3S)- 2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized by peaks in the powder diffraction pattern at the following angles 20, 0(± 0.20°): 12.47, 18.98, 19.92.
[0095] One embodiment of the invention is a crystalline form of the ethyl acetate solvate (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-
[0096] 3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by monoclinic syngony.
[0097] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the space group of the unit crystallographic cell P2b
[0098] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a number of molecules in the unit crystallographic cell Z equal to 2.
[0099] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 12.83±1.92 A; 8.75±1.31 A; 14.90±2.24 A, where each of the parameters represents the length of one of the edges a, b or c.
[0100] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 12.83±0.64 A; 8.75±0.44 A; 14.90±0.75 A, where each of the parameters represents the length of one of the edges a, b or c.
[0101] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 12.83±0.35 A; 8.75±0.20 A; 14.90±0.50 A, where each of the parameters represents the length of one of the edges a, b or c.
[0102] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (II,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 111.01±16.65°, 90.00°, where each of the parameters represents one of the angles between the edges a, or y.
[0103] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1R,28,58)-L[-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 111.01±5.55°, 90.00°, where each of the parameters represents one of the angles between the edges a, 0 or y.
[0104] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1 R,2S,5S)-N-[(1 S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 111.01±2.78°, 90.00°, where each of the parameters represents one of the angles between the edges a, 0 or y.
[0105] One embodiment of the invention is a crystalline form of the ethyl acetate solvate (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a unit cell volume of 1560.00 ± 390.00 A 3 .
[0106] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a unit cell volume of 1560.00 ± 78.00 A 3 .
[0107] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1R,2S,5S)-N-[(1 S)-l-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it is characterized by the following values of the parameters of the unit crystallographic cell: a = 12.83±1.92 Å, b = 8.75±1.31 Å, c = 14.90±2.24; a = 90.00°, p = 111.01±16.65°, y = 90.00°; the volume of the elementary crystallographic cell is 1560.00 A 3 ± 390.00 A 3 .
[0108] In one embodiment of the invention, the parameters of the elementary crystallographic cell were obtained at a temperature of 100 K, which corresponds to - 173.15 °C.
[0109] One embodiment of the invention is a crystalline form of the ethyl acetate solvate of (1,28,58)-Ь1-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it has at least one peak in the powder diffraction pattern at the following angles 20 (± 0.20°): 12.47, 18.06, 18.98, 19.92 or 21.43.
[0110] More preferably, the crystalline form of the ethyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention has peaks at the following 20 angles (± 0.20°) in the powder X-ray diffraction pattern: 12.47, 18.06, 18.98, 19.92, 21.43.
[0111] The stated problem is solved and the claimed technical result is achieved due to the amorphous form of ethyl acetate solvate (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1), characterized by the fact that it has a wide halo in the powder diffraction pattern in the region of angles 20, ° (± 2.00°): 6.00° - 28.00°
[0112] More preferably, the amorphous form of the ethyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide according to the present invention has a broad halo in the powder diffraction pattern in the region of angles 20, ° (± 2.00°): 14.00° - 26.00°.
[0113] One embodiment of the present invention is an amorphous form of the ethyl acetate solvate of (W,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it has a wide halo on the powder diffraction pattern. One embodiment of the present invention is an amorphous form of the ethyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it has a broad halo in the powder diffraction pattern in the form of a set of several blurred maxima.
[0114] One embodiment of the invention is an amorphous form of the ethyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it has a wide halo in the powder diffraction pattern in the form of a set of two diffuse maxima in the region of angles of 20, 0 (± 2.00°): 6.00° - 14.00° and 14.00° - 28.00°.
[0115] More preferably, the amorphous form of the ethyl acetate solvate of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention has a broad halo in the powder diffraction pattern in the form of a set of two diffuse maxima in the region of angles of 20. ° (± 2.00 °): 6.00 ° - 14.00 ° and 15.00 ° - 26.00 °.
[0116] More preferably, the amorphous form of the ethyl acetate solvate of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention has a broad halo in the powder diffraction pattern in the form of a set of two diffuse maxima in the region of angles of 20. ° (± 2.00 °): 6.00 ° - 14.00 ° and 15.00 ° - 25.00 °.
[0117] The stated problem is solved and the claimed technical result is achieved due to the crystalline form of propyl acetate solvate ((28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1), characterized by peaks in the powder diffraction pattern at the following angles 20. ° (± 0.20 °): 12.13, 12.59, 18.97.
[0118] One embodiment of the invention is a crystalline form of the propyl acetate solvate (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by monoclinic syngony. One embodiment of the invention is a crystalline form of the propyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the space group of the unit crystallographic cell P2b
[0119] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2, 2, 2-trifluoroacetyl)amino]butanoyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a number of molecules in the unit crystallographic cell Z equal to 2.
[0120] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1 R,2S,5S)-N-[(1 S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the unit crystallographic cell parameters: 12.80±1.92 A; 8.90±1.34 A; 14.49±2.17 A, where each of the parameters represents the length of one of the edges a, b or c.
[0121] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 12.80±1.28 A; 8.90±0.89 A; 14.49±1.45 A, where each of the parameters represents the length of one of the edges a, b or c.
[0122] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1 R,2S,5S)-N-[(1 S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the unit crystallographic cell parameters: 12.80±0.64 A; 8.90±0.45 A; 14.49±0.71 A, where each of the parameters represents the length of one of the edges a, b or c.
[0123] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 12.80±0.38 A; 8.90±0.23 A; 14.49±0.51 A, where each of the parameters represents the length of one of the edges a, b or c.
[0124] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 104.56±15.68°, 90.00°, where each of the parameters represents one of the angles between the edges a, 0 or y.
[0125] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 104.56±10.46°, 90.00°, where each of the parameters represents one of the angles between the edges a, 0 or y.
[0126] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by the following values of the parameters of the unit crystallographic cell: 90.00°, 104.56±5.23°, 90.00°, where each of the parameters represents one of the angles between the edges a, 0 or y.
[0127] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1K,28,58)-1-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a unit cell volume of 1598.30 ± 399.58 A 3 .
[0128] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a unit cell volume of 1598.30 ± 80.44 A 3 .
[0129] One embodiment of the invention is a crystalline form of the propyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized by a unit cell volume of 1598.30 ± 2.00 A 3 .
[0130] One embodiment of the invention is a crystalline form of the propyl acetate solvate (1R,28,58)-R-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2, 2, 2-trifluoroacetyl)amino]butanoyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it is characterized by the following values of the parameters of the unit crystallographic cell: a = 12.80±1.92 A, b = 8.90±1.34 A, c = 14.49±2.17; a= 90.0°, 0= 104.56±15.68°, y= 90.0°; the volume of the elementary crystallographic cell is 1598.30 A 3 ± 399.58 A 3 .
[0131] More preferably, the crystalline form of the propyl acetate solvate of (1R,28,58)-R-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) according to the present invention has at least one peak at the following 20 angles (± 0.20°) in the powder X-ray diffraction pattern: 11.62, 12.13, 12.59, 18.97 or 19.72.
[0132] More preferably, the crystalline form of propyl acetate solvate (1K,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) according to the present invention has peaks at the following 20 angles (± 0.20°) in the powder X-ray diffraction pattern: 11.62, 12.13, 12.59, 18.97, 19.72.
[0133] The stated problem is solved and the claimed technical result is achieved due to the amorphous form of propyl acetate solvate (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), which is characterized by the fact that it has a wide halo in the region of angles of 20, 0 (± 2.00°): 6.00° - 28.00°.
[0134] One embodiment of the present invention is an amorphous form of the propyl acetate solvate (IR,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, characterized in that it has a wide halo on the powder diffraction pattern.
[0135] One embodiment of the present invention is an amorphous form of the propyl acetate solvate (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized in that it has a wide halo in the powder diffraction pattern in the form of a set of several blurred maxima.
[0136] One embodiment of the present invention is an amorphous form of the propyl acetate solvate (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized in that it has a wide halo in the region of angles 20, 0 (± 2.00°): 7.00 - 26.00°.
[0137] One embodiment of the present invention is an amorphous form of the propyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized in that it has a maximum in the powder diffraction pattern in the form of a wide halo in the region of angles of 20, 0 (± 2.00°): 14.00 - 26.00°.
[0138] One embodiment of the invention is an amorphous form of propyl acetate solvate (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized in that it has a wide halo on the powder diffraction pattern in the form of a set of two diffuse maxima in the region of angles of 20. ° (± 2.00 °): 6.00 ° - 14.00 ° and 14.00 ° - 26.00 °.
[0139] More preferably, the amorphous form of the propyl acetate solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) according to the present invention has a broad halo in the powder diffraction pattern in the form of a set of two diffuse maxima in the region of angles 20. ° (± 2.00 °): 8.00 ° - 13.00 ° and 14.00 ° - 24.00 °.
[0140] In one embodiment of the invention, a powder diffraction pattern was obtained using a diffractometer using monochromatic Ka-radiation of copper.
[0141] In one embodiment of the invention, a powder diffraction pattern was obtained using a diffractometer using monochromatic Ka-radiation of copper at room temperature (20 - 25 °C).
[0142] In one embodiment of the invention, the parameters of the elementary crystallographic cell were obtained at a temperature of 140 K, which corresponds to - 133.15 °C. Infrared spectroscopy, nuclear magnetic resonance spectroscopy, elemental analysis, differential scanning calorimetry, thermogravimetry, powder X-ray diffraction, and single-crystal X-ray diffraction were used to determine the structure of the compounds and the qualitative and quantitative composition of the compositions / mixtures within the framework of the present invention. A portion of the experiments sufficient for analyzing the compounds of the present invention are presented in the examples of the present invention.
[0143] The stated problem is solved, and the claimed technical results are also achieved due to a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing in an effective amount a compound according to the present invention, in particular, characterized by Formula I, or Formula II, or Formula IV, and at least one pharmaceutically acceptable excipient.
[0144] The stated problem is solved and the claimed technical results are also achieved due to a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing in an effective amount a crystalline and / or amorphous form of solvated forms of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, and at least one pharmaceutically acceptable excipient.
[0145] In one embodiment of the present invention, the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide, or dimethyl sulfoxide.
[0146] The stated problem is solved, and the claimed technical results are also achieved by creating a pharmaceutical composition for the treatment and / or prevention of viral diseases, in particular by blocking the activity of the viral protease 3CL, containing at least one of the above-mentioned compounds, characterized by Formula I, or Formula II, or Formula IV, or its structural analogue.
[0147] One of the embodiments of the invention is also a pharmaceutical composition for the treatment and / or prevention of viral diseases, containing as an active agent in an effective amount at least one of the above-mentioned compounds characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof.
[0148] One of the embodiments of the present invention is a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of the viral protease 3CL, containing at least one of the above-mentioned compounds characterized by Formula I, or Formula II, or Formula IV, or its structural analogue in an amount of 0.01 to 99.99 wt. % of the weight of the pharmaceutical composition.
[0149] One of the embodiments of the present invention is a pharmaceutical composition for the treatment and / or prevention of viral diseases, in particular by blocking the activity of 3C-like viral proteases, containing a compound characterized by Formula I, or Formula II, or Formula IV, or its structural analogue in an amount of 0.01 to 99.99 mass % of the mass of the pharmaceutical composition.
[0150] One embodiment of the present invention is a pharmaceutical composition for the treatment and / or prevention of viral diseases, in particular by blocking the activity of 3C-like viral proteases, comprising a crystalline and / or amorphous form of solvated forms of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide, in an amount of from 0.01 to 99.99% by weight of the pharmaceutical composition.
[0151] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV or a structural analogue thereof in said pharmaceutical composition is from 0.01 to 95.00 wt. %, from 0.01 to 90.00 wt. %, from 0.01 to 85.00 wt. %, from 0.01 to 80.00 wt. %, from 0.01 to 75.00 wt. %, from 0.01 to 70.00 wt. %, from 0.01 to 65.00 wt. %, from 0.01 to 60.00 wt. %, from 0.01 to 55.00 wt. %, from 0.01 to 50.00 wt. %, or from 0.01 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0152] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 5.00 to 99.99 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 90.00 wt. %, from 5.00 to 85.00 wt. %, from 5.00 to 80.00 wt. %, from 5.00 to 75.00 wt. %, from 5.00 to 70.00 wt. %, from 5.00 to 65.00 wt. %, from 5.00 to 60.00 wt. %, from 5.00 to 55.00 wt. %, from 5.00 to 50.00 wt. % or from 5.00 to 45.00 mass % of the weight of the pharmaceutical composition.
[0153] More preferably, the content of the compound characterized by Formula I, or Formula II or Formula IV, or a structural analogue thereof in said pharmaceutical composition is from 10.00 to 99.99 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 90.00 wt. %, from 10.00 to 85.00 wt. %, from 10.00 to 80.00 wt. %, from 10.00 to 75.00 wt. %, from 10.00 to 70.00 wt. %, from 10.00 to 65.00 wt. %, from 10.00 to 60.00 wt. %, from 10.00 to 55.00 wt. %, from 10.00 to 50.00 wt. % or from 10.00 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0154] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 15.00 to 99.99 wt. %, from 15.00 to 95.00 wt. %, from 15.00 to 95.00 wt. %, from 15.00 to 90.00 wt. %, from 15.00 to 85.00 wt. %, from 15.00 to 80.00 wt. %, from 15.00 to 75.00 wt. %, from 15.00 to 70.00 wt. %, from 15.00 to 65.00 wt. %, from 15.00 to 60.00 wt. %, from 15.00 to 55.00 wt. %, from 15.00 to 50.00 wt. % or from 15.00 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0155] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 20.00 to 99.99 wt. %, from 20.00 to 95.00 wt. %, from 20.00 to 95.00 wt. %, from 20.00 to 90.00 wt. %, from 20.00 to 85.00 wt. %, from 20.00 to 80.00 wt. %, from 20.00 to 75.00 wt. %, from 20.00 to 70.00 wt. %, from 20.00 to 65.00 wt. %, from 20.00 to 60.00 wt. %, from 20.00 to 55.00 wt. %, from 20.00 to 50.00 wt. % or from 20.00 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0156] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 25.00 to 99.99 wt. %, from 25.00 to 95.00 wt. %, from 25.00 to 90.00 wt. %, from 25.00 to 85.00 wt. %, from 25.00 to 80.00 wt. %, from 25.00 to 75.00 wt. %, from 25.00 to 70.00 wt. %, from 25.00 to 65.00 wt. %, from 25.00 to 60.00 wt. %, from 25.00 to 55.00 wt. %, from 25.00 to 50.00 wt. % or from 25.00 to 45.00 mass % of the weight of the pharmaceutical composition.
[0157] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 30.00 to 99.99 wt. %, from 30.00 to 95.00 wt. %, from 30.00 to 90.00 wt. %, from 30.00 to 85.00 wt. %, from 30.00 to 80.00 wt. %, from 30.00 to 75.00 wt. %, from 30.00 to 70.00 wt. %, from 30.00 to 65.00 wt. %, from 30.00 to 60.00 wt. %, from 30.00 to 55.00 wt. %, from 30.00 to 50.00 wt. % or from 30.00 to 45.00 mass % of the weight of the pharmaceutical composition.
[0158] More preferably, the content of the compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the said pharmaceutical composition is from 35.00 to 99.99 wt. %, from 35.00 to 95.00 wt. %, from 35.00 to 90.00 wt. %, from 35.00 to 85.00 wt. %, from 35.00 to 80.00 wt. %, from 35.00 to 75.00 wt. %, from 35.00 to 70.00 wt. %, from 35.00 to 65.00 wt. %, from 35.00 to 60.00 wt. %, from 35.00 to 55.00 wt. %, from 35.00 to 50.00 wt. % or from 35.00 to 45.00 mass % of the weight of the pharmaceutical composition.
[0159] More preferably, the content of the crystalline and / or amorphous form of the solvated forms of (IR,28,58)-Ln-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide, in the said pharmaceutical composition is from 0.01 to 95.00 mass %, from 0.01 to 90.00 mass %, %, from 0.01 to 85.00 wt. %, from 0.01 to 80.00 wt. %, from 0.01 to 75.00 wt. %, from 0.01 to 70.00 wt. %, from 0.01 to 65.00 wt. %, from 0.01 to 60.00 wt. %, from 0.01 to 55.00 wt. %, from 0.01 to 50.00 wt. % or from 0.01 to 45.00 wt. %; from 5.00 to 99.99 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 90.00 wt. %, from 5.00 to 85.00 wt. %, from 5.00 to 80.00 mass. %, from 5.00 to 75.00 mass.%, from 5.00 to 70.00 wt. %, from 5.00 to 65.00 wt. %, from 5.00 to 60.00 wt. %, from 5.00 to 55.00 wt. %, from 5.00 to 50.00 wt. % or from 5.00 to 45.00 wt. %; from 10.00 to 99.99 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 90.00 wt. %, from 10.00 to 85.00 wt. %, from 10.00 to 80.00 wt. %, from 10.00 to 75.00 wt. %, from 10.00 to 70.00 wt. %, from 10.00 to 65.00 wt. %, from 10.00 to 60.00 wt. %, from 10.00 to 55.00 wt. %, from 10.00 to 50.00 wt. % or from 10.00 to 45.00 wt. %; from 15.00 to 99.99 wt. %, from 15.00 to 95.00 wt. %, from 15.00 to 95.00 wt. %, from 15.00 to 90.00 wt. %, from 15.00 to 85.00 wt. %, from 15.00 to 80.00 wt. %, from 15.00 to 75.00 wt. %, from 15.00 to 70.00 wt. %, from 15.00 to 65.00 wt. %, from 15.00 to 60.00 wt. %, from 15.00 to 55.00 wt. %, from 15.00 to 50.00 wt. % or from 15.00 to 45.00 wt. %; from 20.00 to 99.99 wt. %, from 20.00 to 95.00 wt. %, from 20.00 to 95.00 wt. %, from 20.00 to 90.00 wt.%, from 20.00 to 85.00 wt. %, from 20.00 to 80.00 wt. %, from 20.00 to 75.00 wt. %, from 20.00 to 70.00 wt. %, from 20.00 to 65.00 wt. %, from 20.00 to 60.00 wt. %, from 20.00 to 55.00 wt. %, from 20.00 to 50.00 wt. % or from 20.00 to 45.00 wt. %; from 25.00 to 99.99 wt. %, from 25.00 to 95.00 wt. %, from 25.00 to 90.00 wt. %, from 25.00 to 85.00 wt. %, from 25.00 to 80.00 wt. %, from 25.00 to 75.00 wt. %, from 25.00 to 70.00 wt. %, from 25.00 to 65.00 wt. %, from 25.00 to 60.00 wt. %, from 25.00 to 55.00 wt. %, from 25.00 to 50.00 wt. % or from 25.00 to 45.00 wt. %; from 30.00 to 99.99 wt. %, from 30.00 to 95.00 wt. %, from 30.00 to 90.00 wt. %, from 30.00 to 85.00 wt. %, from 30.00 to 80.00 wt. %, from 30.00 to 75.00 wt. %, from 30.00 to 70.00 wt. %, from 30.00 to 65.00 wt. %, from 30.00 to 60.00 wt. %, from 30.00 to 55.00 wt. %, from 30.00 to 50.00 wt. % or from 30.00 to 45.00 wt. %; from 35.00 to 99.99 wt. %, from 35.00 to 95.00 wt. %, from 35.00 to 90.00 wt.%, from 35.00 to 85.00 wt. %, from 35.00 to 80.00 wt. %, from 35.00 to 75.00 wt. %, from 35.00 to 70.00 wt. %, from 35.00 to 65.00 wt. %, from 35.00 to 60.00 wt. %, from 35.00 to 55.00 wt. %, from 35.00 to 50.00 wt. % or from 35.00 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0160] One of the embodiments of the invention is also a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of the viral protease 3CL, containing in an effective amount a compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof, and at least one pharmaceutically acceptable excipient.
[0161] One embodiment of the invention is the above-mentioned pharmaceutical composition for the treatment and / or prevention of viral diseases, characterized in that the pharmaceutically acceptable excipients are selected from the group comprising formulators, stabilizers, solubilizers, solvents, humectants, lubricants, slip agents, thickeners, sweeteners, flavorings, aromatizers, fungicides, prolonged delivery regulators, co-solvents, diluents, fillers, emulsifiers, preservatives, antioxidants, buffering agents, cryoprotectants, pH-regulating agents, substances for maintaining isotonicity or correcting substances.
[0162] One embodiment of the invention is the above-mentioned pharmaceutical composition for the treatment and / or prevention of viral diseases, characterized in that the pharmaceutically acceptable excipient is water, for example, but not limited to, injection water, apyrogenic water or distilled water.
[0163] One embodiment of the present invention is a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of the viral protease 3CL, containing at least one pharmaceutically acceptable excipient in an amount of 0.01 to 99.99 wt. % of the weight of the pharmaceutical composition. One embodiment of the present invention is a pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing at least one pharmaceutically acceptable excipient in an amount of 0.01 to 99.99 wt. % of the weight of the pharmaceutical composition.
[0164] More preferably, the content of at least one pharmaceutically acceptable excipient in said pharmaceutical composition is 0.01 to 95.00 wt. %, from 0.01 to 95.00 wt. %, from 0.01 to 90.00 wt. %, from 0.01 to 85.00 wt. %, from 0.01 to 80.00 wt. %, from 0.01 to 75.00 wt. %, from 0.01 to 70.00 wt. %, from 0.01 to 65.00 wt. %, from 0.01 to 60.00 wt. %, from 0.01 to 55.00 wt. %, from 0.01 to 50.00 wt. %, or from 0.01 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0165] More preferably, the content of at least one pharmaceutically acceptable excipient in said pharmaceutical composition is from 5.00 to 99.99 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 95.00 wt. %, from 5.00 to 90.00 wt. %, from 5.00 to 85.00 wt. %, from 5.00 to 80.00 wt. %, from 5.00 to 75.00 wt. %, from 5.00 to 70.00 wt. %, from 5.00 to 65.00 wt. %, from 5.00 to 60.00 wt. %, from 5.00 to 55.00 wt. %, from 5.00 to 50.00 wt. %, or from 5.00 to 45.00 wt. % of the weight of the pharmaceutical composition.
[0166] More preferably, the content of at least one pharmaceutically acceptable excipient in said pharmaceutical composition is from 10.00 to 99.99 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 95.00 wt. %, from 10.00 to 90.00 wt. %, from 10.00 to 85.00 wt. %, from 10.00 to 80.00 wt. %, from 10.00 to 75.00 wt. %, from 10.00 to 70.00 wt. %, from 10.00 to 65.00 wt. %, from 10.00 to 60.00 wt. %, from 10.00 to 55.00 wt. %, from 10.00 to 50.00 wt. % or from 10.00 to 45.00 mass % of the weight of the pharmaceutical composition.
[0167] The stated task is solved, and the claimed technical results are also achieved by creating a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of the viral protease 3CL, containing at least one compound characterized by Formula I, or Formula II, or Formula IV, or its structural analogue.
[0168] The stated problem is solved and the claimed technical results are also achieved by creating a medicinal product for the treatment and / or prevention of viral diseases, containing an effective amount of a compound selected from the group consisting of compounds characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof. The stated problem is solved and the claimed technical results are also achieved by a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing an effective amount of a compound selected from the group consisting of compounds characterized by Formula I, Formula II or Formula IV, and, if necessary, at least one pharmaceutically acceptable excipient.
[0169] The stated problem is solved and the claimed technical results are also achieved due to a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing in an effective amount a crystalline and / or amorphous form of the solvated form of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide compound, and, if necessary, at least at least one pharmaceutically acceptable excipient.
[0170] Preferably, the ratio of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide to the solvating solvent in the solvated form of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide of the present invention is (1:1 by moles).
[0171] One embodiment of the present invention is a medicinal product for the treatment and / or prevention of viral diseases which contains pharmaceutically acceptable excipients selected from the group consisting of excipients, stabilizers, solubilizers, solvents, humectants, lubricants, slip agents, thickeners, sweeteners, flavors, aromas, fungicides, prolonged delivery regulators, co-solvents, diluents, fillers, emulsifiers, preservatives, antioxidants, buffering agents, cryoprotectants, pH-regulating agents, substances for maintaining isotonicity or correcting substances.
[0172] One embodiment of the present invention is a medicinal product for the treatment and / or prevention of viral diseases, containing at least one compound characterized by Formula I, or Formula II, or Formula IV, or its structural analogue in an amount of 40 to 4000 mg.
[0173] More preferably, the content of at least one compound characterized by Formula I or Formula II or Formula IV or a structural analogue thereof in the medicament of the present invention is from 40 to 3800 mg, from 40 to 3600 mg, from 40 to 3400 mg, from 40 to 3200 mg, from 40 to 3000 mg, from 40 to 2800 mg, from 40 to 2600 mg, from 40 to 2400 mg, from 40 to 2200 mg, from 40 to 2000 mg, from 40 to 1800 mg, from 40 to 1600 mg, from 40 to 1400 mg, from 40 to 1200 mg, from 40 to 1000 mg, from 40 to 800 mg, from 40 to 600 mg or from 40 to 400 mg.
[0174] More preferably, the content of at least one compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in the medicinal product of the present invention is from 100 to 400 mg.
[0175] More preferably, the content of at least one crystalline and / or amorphous form of the solvated form of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2B)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide of the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide, in the medicament of the present invention is from 40 to 4000 mg, from 40 to 3800 mg, from 40 to 3600 mg, 40 to 3400 mg, 40 to 3200 mg, 40 to 3000 mg, 40 to 2800 mg, 40 to 2600 mg, 40 to 2400 mg, 40 to 2200 mg, 40 to 2000 mg, 40 to 1800 mg, 40 to 1600 mg, 40 to 1400 mg, 40 to 1200 mg, 40 to 1000 mg, 40 to 800 mg, 40 to 600 mg, 40 to 400 mg, or 100 to 400 mg.
[0176] In one embodiment of the present invention, an effective dosage of the active agent for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases is in the range of about 30 to 7000 mg per day per patient in need of such treatment.
[0177] More preferably, the effective dosage of the active agent of the present invention is from 50 to 7000, from 100 to 7000, from 150 to 7000, from 200 to 7000, from 300 to 7000, from 400 to 7000, from 500 to 7000, from 1000 to 7000, from 1200 to 7000, from 1500 to 7000, from 2000 to 7000, from 2200 to 7000, from 2500 to 7000, from 3000 to 7000, from 3200 to 7000, from 3500 to 7000, from 4000 to 7000, from 4200 to 7000, 4500 to 7000, 5000 to 7000 or 5500 to 7000 mg per day per patient in need of such treatment. More preferably, the effective dosage of the active agent of the present invention is 50 to 4000, 70 to 3500, 100 to 3000, 120 to 2500, 150 to 2000, 170 to 1500, 200 to 1200, 200 to 1000, 200 to 800, 200 to 600 mg per day per patient in need of such treatment.
[0178] If necessary, doses are usually divided into several smaller doses to be administered throughout the day.
[0179] One embodiment of the present invention is a medicinal product for the treatment and / or prevention of viral diseases, containing at least one compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof in an amount of 10.00 to 85.00% by weight of the medicinal product.
[0180] One embodiment of the present invention is a medicament for the treatment and / or prevention of viral diseases, comprising at least one crystalline and / or amorphous form of the solvated form of (1R,2S,5S)- N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide, in an amount of from 10.00 to 85.00% by weight of the medicament.
[0181] One embodiment of the present invention is a medicament for the treatment and / or prevention of viral diseases, comprising at least one compound characterized by Formula I, or Formula II, or Formula IV, or a structural analogue thereof, and at least one pharmaceutically acceptable excipient, in an amount of from 15.00 to 90.00 wt. %, from 15.00 to 85.00 wt. %; from 15.00 to 80.00 wt. %; from 15.00 to 75.00 wt. %; from 15.00 to 70.00 wt. %; from 15.00 to 65.00 wt. %; from 15.00 to 60.00 wt. %; from 15.00 to 55.00 wt. %; from 15.00 to 50.00 wt. %; from 15.00 to 45.00 wt.% or from 15.00 to 40.00 wt.% of the weight of the medicinal product.
[0182] One embodiment of the present invention is a medicament for the treatment and / or prevention of viral diseases, comprising at least one crystalline and / or amorphous form of the solvated form of (1R,2S,5S)- N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide, and at least one pharmaceutically acceptable excipient, in an amount of from 15.00 to 90.00 wt. %, 15.00 to 85.00 wt. %; 15.00 to 80.00 wt. %; 15.00 to 75.00 wt. %; 15.00 to 70.00 wt. %; 15.00 to 65.00 wt. %; 15.00 to 60.00 wt. %; 15.00 to 55.00 wt. %; 15.00 to 50.00 wt. %; 15.00 to 45.00 wt. % or 15.00 to 40.00 wt.% of the mass of the drug.
[0183] The stated problem is solved, and the claimed technical results are also achieved by creating a medicinal product for the treatment and / or prevention of viral diseases, containing in an effective amount a pharmaceutical composition according to the present invention and at least one pharmaceutically acceptable excipient.
[0184] The stated task is solved, and the stated technical results are also achieved by creating a medicinal product for the treatment and / or prevention of viral diseases, containing the above-mentioned pharmaceutical composition in an effective amount.
[0185] One embodiment of the present invention is a medicament for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, comprising the above-mentioned pharmaceutical composition in an amount of from 40 to 5000 mg, more preferably from 40 to 4800 mg; from 40 to 4600 mg; from 40 to 4400 mg; from 40 to 4200 mg; from 40 to 4000 mg; from 40 to 3800 mg; from 40 to 3600 mg; from 40 to 3400 mg; from 40 to 3200 mg; from 40 to 3000 mg; from 40 to 2800 mg; from 40 to 3600 mg; from 40 to 3400 mg; from 40 to 3200 mg; from 40 to 3000 mg; from 40 to 2800 mg; from 40 to 2600 mg; from 40 to 2400 mg; from 40 to 2200 mg; from 40 to 2000 mg; from 40 to 1800 mg; from 40 to 1600 mg; from 40 to 1400 mg; from 40 to 1200 mg; from 40 to 1000 mg; from 40 to 800 mg; from 40 to 600 mg; from 40 to 400 mg; from 100 to 400 mg.
[0186] One embodiment of the present invention is a medicament for the treatment and / or prevention of viral diseases, comprising the above-mentioned pharmaceutical composition in an amount of from 10.00 to 95.00 wt. %, more preferably from 10.00 to 90.00 wt. %; from 10.00 to 85.00 wt. %; from 10.00 to 80.00 wt. %; from 10.00 to 75.00 wt. %; from 10.00 to 70.00 wt. %; from 10.00 to 65.00 wt. %; from 10.00 to 60.00 wt. %; from 10.00 to 55.00 wt. %; from 10.00 to 50.00 wt. %; from 10.00 to 45.00 wt. %; from 10.00 to 40.00 mass % of the mass of the medicinal product.
[0187] One embodiment of the present invention is a medicinal product that is a solid medicinal product. More preferably, the solid medicinal product of the present invention is, but is not limited to, a tablet, capsule, pellet, dragee, granule, sachet, lyophilisate or powder.
[0188] More preferably, the solid preparation of the present invention is, but is not limited to, a dispersible tablet including an orodispersible tablet, a lyophilized tablet, a film-coated tablet, a buccal tablet, an effervescent tablet, a delayed / extended / modified release tablet.
[0189] One embodiment of the invention is a medicinal product that is a liquid medicinal product.
[0190] One embodiment of the present invention is a liquid medicinal product in the form of a concentrate.
[0191] The concentrate of the present invention, obtained including by reconstitution of the lyophilisate, is in turn diluted to a solution that is suitable for injection or infusion into a patient.
[0192] One embodiment of the present invention is a medicinal product that is a parenteral medicinal product.
[0193] More preferably, the parenteral drug of the present invention is, but is not limited to, an infusion solution, an injection solution, an inhalation drug including an aerosol, a spray or a powder.
[0194] The stated problem is solved and the stated technical results are achieved through the use of the pharmaceutical composition according to the present invention for obtaining a medicinal product for the treatment and / or prevention of viral diseases.
[0195] The stated problem is solved and the claimed technical results are achieved by using the pharmaceutical composition according to the present invention to obtain a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of the viral protease 3CL.
[0196] The stated problem is solved and the claimed technical results are achieved by using the pharmaceutical composition according to the present invention to obtain a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
[0197] More preferably, the viral disease of the present invention is caused by a coronavirus. More preferably, the viral disease of the present invention is caused by the SARS-CoV-2 virus.
[0198] The stated problem is solved and the claimed technical results are achieved by using at least one compound characterized by Formula I, or Formula II, or Formula IV, or its structural analogue according to the present invention for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
[0199] The stated problem is solved and the claimed technical results are achieved by using at least one crystalline and / or amorphous form of the solvated form of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide compounds, for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
[0200] The stated problem is solved and the claimed technical results are achieved by using at least one compound characterized by Formula I, or Formula II, or Formula III, or Formula IV, or its structural analogue according to the present invention in the composition of a pharmaceutical composition contained in a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
[0201] The stated problem is solved and the claimed technical results are achieved through the use of a pharmaceutical composition and / or medicinal product according to the present invention for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
[0202] More preferably, the viral disease of the present invention is caused by a picornavirus, norovirus, foot-and-mouth disease virus, hepatitis A virus, poliovirus, rhinovirus, enterovirus, calicivirus or coronavirus.
[0203] More preferably, the viral disease of the present invention is caused by a coronavirus.
[0204] More preferably, the viral disease of the present invention is caused by the SARS-CoV-2 virus.
[0205] The stated problem is solved and the claimed technical results are achieved by using a compound characterized by Formula I, or Formula II, or Formula IV, or its structural analogue according to the present invention, to obtain a pharmaceutical composition for the treatment and / or prevention of viral diseases.
[0206] The stated problem is solved and the claimed technical results are achieved by using a crystalline and / or amorphous form of the solvated form of (IB,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, wherein the solvating solvent is ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, hydrate, diethyl ether, dimethylformamide or dimethyl sulfoxide compound for the production of a pharmaceutical composition for the treatment and / or prevention of viral diseases.
[0207] The following are examples of the invention, which illustrate the invention, but do not cover all possible variants of its implementation and do not limit the invention.
[0208] A person skilled in the art will understand that other specific embodiments of the invention are also possible.
[0209] Examples
[0210] Example 1. Obtaining new forms of azabicyclohexane derivatives.
[0211] In an extensive study of the recrystallization process of the azabicyclohexane derivatives of the present invention, in particular, but not limited to, (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and its derivatives, the inventors, expecting to obtain a chemically pure powder of the azabicyclohexane derivatives, unexpectedly discovered new forms of the azabicyclohexane derivatives, namely, new solvates of the azabicyclohexane derivatives. Some of them had improved physicochemical and / or technological and / or pharmacological properties.
[0212] All reactions were carried out in solvents purified according to standard methods. Ika C-MAG HS 7 Package magnetic stirrers with temperature control, Stegler 2VP-2 laboratory vacuum pump, BUCHI Rotavapor® R-300 rotary evaporator with Buchi V-600 membrane pump, Bandelin RK 1028 Sonorex Super ultrasonic bath were used to carry out the reactions. Diffraction data were recorded on a Broker Quest single-crystal three-circle diffractometer, year of manufacture 2019, equipped with a microfocus molybdenum source and a Photon III coordinate two-dimensional detector with an aperture of 10x14 cm with the ability to automatically control the detector-sample distance. The device is controlled by the Bruker APEX3 complex.
[0213] X-ray phase analysis was performed on a Bruker D8 Advance powder diffractometer equipped with a Theta / 2Theta goniometer for measurements in the Bragg-Brentano “reflection” geometry. The diameter of the Theta goniometric axis is 500 mm. The device is equipped with a LynxEye one-dimensional coordinate detector with an aperture of 3° and a rotary sample holder for rotating the sample at an adjustable speed.
[0214] Thermal stability of the sample was studied by thermogravimetric analysis (TGA / DSC) using a thermal imager SDT Q600 V8.3 Build 101 Module DSC-TGA. The sample was heated at 10°C / min from 25 to 300°C and an air flow of 250 ml / min in an open aluminum vessel.
[0215] The experiment was carried out as follows. The calculated amount of the azabicyclohexane derivatives of the present invention, obtained according to the method indicated below, or, in a particular embodiment, commercially available (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, was dispersed in solvent A, or in solvent B, or in a mixture of solvents A and B at a volume ratio of A:B equal to 1:1 - 1:100 at a temperature of 20 - 50 °C. Stirring and, if necessary, ultrasonic treatment were used for better dissolution. The mixture was then diluted with solvent B in an amount of approximately 20% of the volume of mixture A+B and gradually cooled with a step of 5°C / hour to 0°C. After 24 hours, the precipitate was separated by filtration with washing with solvent A. The precipitate was then dried in a stream of nitrogen, obtaining a product in the form of a powder.
[0216] Solvent A: cyclohexane, dioxane, heptane, hexane, isooctane, methyl ethyl ketone, pentane, toluene, acetonitrile, acetone, methanol, ethanol, butanol, isopropanol, tetrahydrofuran, DMSO or ethyl acetate.
[0217] Solvent B: methanol, ethanol, isopropanol, trifluoroethanol, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, amyl acetate, toluene, formamide, tetrahydrofuran, chloroethyl acetate, acetone, acetonitrile, dichloroethane, 2, 2, 3,3,3-pentafluoro-1-propanol, 2, 2,3,3 ,3 ,4,4,4-heptafluoro-1-butanol, 2,2,3 ,3-tetrafluoro-1-propanol, 2,2,3,4,4,4-hexafluoro-1-butanol, DMF, DMSO, water or diethyl ether. Solvates of azabicyclohexane derivatives according to the present invention, in particular solvates of compounds characterized by Formula II according to the present invention, were prepared in the following manner. Azabicyclohexane derivative according to the present invention, in particular characterized by Formula II according to the present invention (50 mg) was dispersed in a mixture of solvents A and B in given ratios and quantities at a given temperature, indicated in Tables 1, 3-6. For better homogenization, stirring and, if necessary, ultrasonic treatment were used.The mixture was then diluted with solvent B (2 ml) and gradually cooled with a step of 5 °C / hour to 0 °C. After 24 hours, the precipitate was separated by filtration with washing with dioxane. The precipitate was then dried in a stream of nitrogen, obtaining the product in the form of a homogeneous powder.
[0218] In a particular case of the implementation of the present invention, to obtain the butyl acetate solvate of (1K,28,58)- -[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:3) (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dispersed in a mixture of dioxane and butyl acetate (10 ml) at a weight ratio of dioxane to butyl acetate of 1:1 at 45°C. Stirring and, if necessary, ultrasonic treatment were used to better homogenize the dissolution. Then the mixture was diluted with butyl acetate (2 ml) and gradually cooled in increments of 5°C / hour to 0°C. After 24 hours, the precipitate was separated by filtration and washed with dioxane. Then the precipitate was dried in a stream of nitrogen, and the product was obtained as a homogeneous powder.
[0219] Similarly, by varying the reaction conditions in the indicated ranges, other solvates of the azabicyclohexane derivatives of the present invention were obtained (according to Table 1, 3-6).
[0220] The chemical composition of the obtained products was identified using the !H, 13 With NMR, elemental analysis. The results of the experiments are presented in Table 2, 7-10.
[0221] Table 1. Crystallization of new forms of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0222]
[0223] In a similar manner to the above method, under the specified reaction conditions, other solvates were also obtained according to the present invention, with the amount of solvating solvent from 0.5-3.0. The following groups of solvents were used: Solvent A: cyclohexane, dioxane, heptane, hexane, isooctane, methyl ethyl ketone, acetonitrile, acetone, methanol, ethanol, butanol, tetrahydrofuran, DMSO or ethyl acetate.
[0224] Solvent B: methanol, ethanol, ethyl acetate, propyl acetate, butyl acetate, isobutyl acetate, tetrahydrofuran, acetone, acetonitrile, DMF, DMSO, water or diethyl ether.
[0225] Or a mixture of solvents A and B selected from the list: hexane / methanol; dioxane / methanol; heptane / ethyl acetate; acetonitrile / ethyl acetate; acetone / ethyl acetate; ethanol / butyl acetate; dioxane / butyl acetate; isooctane / tetrahydrofuran; hexane / tetrahydrofuran; methyl ethyl ketone / acetone; butanol / acetone; cyclohexane / acetonitrile; isooctane / acetonitrile; acetone / isobutyl acetate; butanol / isobutyl acetate; dioxane / propyl acetate; methanol / propyl acetate; acetone / DMF; ethyl acetate / DMF; ethanol / DMSO; acetonitrile / ethanol; acetone / ethanol; tetrahydrofuran / ethanol; DMSO / water; methanol / water; methyl ethyl ketone / diethyl ether.
[0226] Identification of some of the products obtained according to the above described method is presented below in Table 2.
[0227] Table 2. Identification of products by methods H, 13 With NMR, elemental analysis.
[0228] Based on the results of the experiments, it was possible to investigate the ability of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide to form solvates. A wide range of solvents and their combinations were used to obtain solvates in the synthesis, but the formation of solvates of (1N,28,58)-P-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was only possible using the above list of solvents under certain conditions, some versions of which are shown in experiments 1, 5, 6, 10, 12, 13, 15, 18, 23, 24, 25, 26, 27. In certain experiments, when using other solvents and reaction conditions, the formation of solvates did not occur, contrary to expectations. was observed.
[0229] The product of experiment 13, according to the results of the conducted analytical studies, was acetonitrile solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide 1:1. It was not used in further experiments, since it was extremely unstable (after 6 hours of storage, the sample changed its appearance and lost its structural homogeneity). Further studies showed the loss of solvation solvent, which made it possible to establish the low stability of the resulting acetonitrile solvate.
[0230] In experiments 2-4, 7-9, 11, 14, 16, 17, 19-22, it was possible to record the formation of ( 1 R,2S,5 S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3 -yl]ethyl]-3-[(2S)-3 ,3 - dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in a form free of solvation solvent.
[0231] Within the framework of the present invention, new derivatives of azabicyclohexane were also obtained and studied according to the general synthesis schemes indicated below in the text, and their new solvated forms were also obtained and studied.
[0232] General schemes for the synthesis of azabicyclohexane derivatives according to the present invention: where Ri', R2', R3', R4' are radicals corresponding to the radicals R3, R4, Rs, R6 according to the present invention.
[0233] In a particular case of implementing the invention in a similar manner to that indicated earlier in this application, studies were carried out on the recrystallization process of (1R,2S,5S)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, (1R,2S,5S)-N-{(1S)-1-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[-(chlorodifluoroacetyl)-β-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, (lR,2S,5S)-N-{(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-β-seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, (lR,2S,5S)-N-{(lS)-l-pHaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-β-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, obtained according to the following synthetic approaches.
[0234] Step 1. Synthesis of methyl (1 ,28,58)-3-^-(tert-butoxycarbonyl)- -valyl]-6,6- dimethyl 3-azabicyclo[3.1.0]hexane-2-carboxylate (Zla); Synthesis of methyl (1H,28,58)-3-
[0235] [1H-(tert-butoxycarbonyl)-b-phenylalanyl]-6,6-dimethyl-3-azabicycle o[3.1.0]hexane-2-carboxylate (Zlb); Synthesis of methyl-(1,28,58)-3-^-(tert-butoxycarbonyl)- -seryl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate (Zlc).
[0236] A solution of ]-(tert-butoxycarbonyl)-L-valine (commercially available) (100.0 g) to obtain Zla; LT-(tert-butoxycarbonyl)-L-phenylalanine (commercially available) (100.0 g) to obtain Zlb; LT-(tert-butoxycarbonyl)-β-serine (commercially available) (100.0 g) to obtain Zlc in a mixture of acetonitrile and LT-dimethylformamide (10:1 ratio by volume, 1.5 L) were treated sequentially with O-(7-azabenzotriazol-1-yl)-N,T\[,LT,N-tetramethyluronium hexafluorophosphate (HATU) (1 equiv.) at 0°C and N,N-diisopropylethylamine (2.3 equiv.). After stirring the reaction mixture for 5 min, methyl (1N,28,58)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride salt (0.9 equiv) was added and stirring was continued at 0°C for 1 h. The reaction mixture was then successively diluted with aqueous citric acid (1 N, 70.0 mL) and water (140.0 mL), stirred for 2 min, and concentrated in vacuo to approximately half the original volume.The mixture was extracted three times with ethyl acetate, the organic phase was combined and washed three times with water and once with a saturated aqueous solution of sodium chloride. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The concentrate was dissolved in a minimum amount of ethyl acetate and then filtered; the insoluble residue was washed with ethyl acetate until it turned white. The filtrates were combined and concentrated under reduced pressure (220-260 mbar). The products were isolated by column chromatography on silica gel (eluent: 1:1 - 2:3 ethyl acetate / heptane) to give products Z 1 a / Z 1 b / Z 1 c .
[0237] The yield is quantitative. The products were identified using LCMS m / z 369.2 [M+H] + for Zla; m / z 417.3 [M+H] + for Zlb; m / z 357.2 [M+H] + for Zlc.
[0238] Step 2. Synthesis of methyl (1 ,28,58)-6,6-dimethyl-3-β-valyl-3-azabicyclo[3.1.0]hexane-2-carboxylate, hydrochloride salt (Z2a); methyl (1R,28,58)-6,6-dimethyl-3-β-phenylalanyl-3-azabicyclo[3.1.0]hexane-2-carboxylate, hydrochloride salt (Z2b); methyl (1R,28,58)-6,6-dimethyl-3-E-seryl-3-azabicyclo[3.1.0]hexane-2-carboxylate, hydrochloride salt (Z2c).
[0239] To a solution of Zla (1.4 g) to obtain Z2a; Zlb (1.4 g) to obtain Z2b; Zlc (1.4 g) to obtain Z2c in ethyl acetate was added a solution of hydrogen chloride in 1,4-dioxane (4 M, 20 equiv.) at 0 °C. The reaction mixture was stirred at constant temperature for 2 h, after which an additional amount of hydrogen chloride in 1,4-dioxane (4 M, 14 equiv.) was added and stirring was continued at 0 °C for 3 h, then at room temperature for 1 h. The reaction mixture was concentrated in vacuo to give Z2a; Z2b; Z2c as a gum. The obtained products were used in the next step without further purification.
[0240] The yield is quantitative. The product was identified by LCMS m / z 269.2 [M+H] + for Z2a; 317.3 [M+H] + for Z2b; 257.2 [M+H] + for Z2c.
[0241] Stage 3. Synthesis of methyl-(R,28,58)-6,6-dimethyl-3-[1N-(trifluoroacetyl)-b-valyl.1|-3-azabicyclo[3.1,0]hexane-2-carboxylate (Z3a); methyl-(1,28,58)-6,6-dimethyl-3-[]H-(chlorodifluoroacetyl)-b-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxylate (Z3b); methyl-(1,28,58)-6,6-dimethyl-3-[N-(trifluoroacetyl)-seryl]-3-azabicyclo[3.1,0]hexane-2-carboxylate (Z3c); methyl-(1R,28,58)-6,6-dimethyl-3-[N-(trifluoroacetyl)-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxylate (Z3d).
[0242] To a solution of Z2a (1.4 g) to obtain Z3a; Z2b (1.4 g) to obtain Z3b and Z3d; Z2c (1.4 g) to obtain Z3c in dichloromethane (51 mL) was added triethylamine (3 equiv.) at 0 °C, followed by dropwise addition of trifluoroacetic anhydride (1.2 equiv.) to obtain Z3a, Z3c, Z3d chlorodifluoroacetic anhydride (1.2 equiv.) Z3b over 30 min. The reaction mixture was stirred at 0 °C for 30 min, then diluted with dichloromethane (140 mL), washed successively with 10% aqueous potassium bisulfate solution (70 mL) and saturated aqueous sodium chloride solution (42 mL), dried over sodium sulfate, filtered and concentrated in vacuo. Products Z3a; Z3b; Z3c; Z4d were obtained as light yellow oil.
[0243] The yield is quantitative. The products were identified using LCMS m / z 365.2 [M+H] + for Z3a; 429.2 [M+H] + for Z3b; 353.1 [M+H] + for Z3c; 413.2 [M+H] + for Z3d.
[0244] Step 4. Synthesis of (1 ,28,58)-6,6-dimethyl-3-[N-(trifluoroacetyl)-β-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (Z4a); (1R,28,58)-6,6-dimethyl-3-[N-(chlorodifluoroacetyl)-β-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (Z4b); (1 ,28,58)-6,6-dimethyl-3-[N-(trifluoroacetyl)-β-seryl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (Z4c); (1 ,28,58)-6,6-dimethyl-3-[X-(chlorodifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (Z4d).
[0245] To a solution of Z3a (1.1 g) to obtain Z4a; Z3b (1.1 g) to obtain Z4b; Z3c (1.1 g) to obtain Z4c; Z3d (1.1 g) to obtain Z4d in tetrahydrofuran (50 ml) was added lithium hydroxide (2 equiv.) in small portions at 0 °C. Then the reaction mixture was warmed to room temperature and stirred for 2 hours, after which 10% sulfuric acid solution was added to the reaction mixture until pH = 3-4 and evaporated on a rotary evaporator. Then the reaction mixture was extracted with ethyl acetate, the organic phase was collected over sodium sulfate, filtered, concentrated in vacuo to obtain products Z4a; Z4b; Z4c, Z4d as a white substance. Products Z4a; Z4b; Z4c, Z4d were used in the next step without further purification.
[0246] Yield 83% for Z4a; 64% for Z4b; 72% for Z4c. Product identification was performed by LCMS m / z 351.2 [M+H] + for Z4a; 415.2 [M+H] + for Z4b; 339.1 [M+H] + for Z4c; 399.2 [M+H] + for Z4d.
[0247] Step 5. Synthesis of tert-butyl{(28)-1-amino-1-oxo-3-[(38)-2-oxopyrrolidin-3-yl]propan-2-yl}carbamate (Z5).
[0248] To a solution of methyl N-(tert-butoxycarbonyl)-3-[(38)-2-oxopyrrolidin-3-yl]- - alaninate (7.0 g) in methanol (35.0 mL) was added a solution of ammonia in methanol (7.0 M, 210.0 mL). The reaction mixture was stirred at room temperature for 3 days and concentrated in vacuo. The concentrate was dissolved in a mixture of ethyl acetate and heptane (1:1 ratio by volume, 280.0 mL) and precipitated with heptane (70.0 mL) to give the product Z5 as a solid. The obtained product was used in the next step without further purification. Identification of the product was not carried out at this step; the structure of the product was controlled at the next step.
[0249] Step 6. Synthesis of tert-butyl {(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}carbamate (Z6).
[0250] To a solution of Z5 (1.4 g) in dichloromethane (17.0 mL) were added 2,6-dimethylpyridine (3.0 mL) and trifluoroacetic anhydride (2 equiv.) at 0 °C. The reaction mixture was stirred at room temperature for 1.5 h, then treated with hydrochloric acid (1 M, 42.0 mL) and diluted with dichloromethane (85.0 mL). The organic layer was washed successively with saturated aqueous sodium chloride solution (35.0 mL), saturated aqueous sodium bicarbonate solution (35.0 mL), dried over sodium sulfate and concentrated in vacuo. The product was isolated by column chromatography on silica gel using a gradient eluting from 40% to 100% ethyl acetate in heptane to afford Z6 as a solid.
[0251] Yield: 88% in step 2. Product identification was performed by LCMS m / z 254.3 [M+H] + .
[0252] Step 7. Synthesis of (28)-2-amino-3-[(38)-2-oxopyrrolidin-3-yl]propanenitrile, methanesulfonate salt (Z7).
[0253] Methanesulfonic acid (1 equiv) was added to a solution of Z6 (0.4 mL) in 1,1,1,3,3,3-hexafluoropropan-2-ol (5.0 mL). The reaction mixture was stirred at room temperature for 45 min, concentrated in vacuo, redissolved in acetonitrile:ethyl acetate (1:1 v / v, 30.0 mL) and concentrated, then dissolved in ethyl acetate:heptane (1:1 v / v, 30.0 mL) and concentrated. The product Z7 was obtained as a glassy film. This product was used in the next step without further purification.
[0254] The product was identified by LCMS m / z 154.2 [M+H] + .
[0255] Stage 8. Synthesis of (1R,28,58)-NH-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3- [1N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z28) / (1 ,28,58)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3- [X-(chlorodifluoroacetyl)- -phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z38) / (1K,28,58)-1H-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3- [1-(trifluoroacetyl)- -seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z48) / (1K,28,58)^-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-
[0256] (trifluoroacetyl)-b-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z58).
[0257] The products Z7 and Z4a (1 equiv: 1 equiv) to obtain Z28; Z7 and Z4b (1 equiv: 1 equiv) to obtain Z38; Z7 and Z4c (1 equiv: 1 equiv) to obtain Z48; Z7 and Z4d (1 equiv: 1 equiv) to obtain Z58 were dissolved in acetonitrile so that the concentration of the solution was 0.2 mmol / ml, cooled to 0°C, O-(7-azabenzotriazol-1-yl)-N,N,N',N-tetramethyluronium hexafluorophosphate (HATU) (1 equiv) was added to the resulting solution, then a solution of 4-methylmorpholine (3 equiv) in acetonitrile (solution concentration 1.7 mmol / ml). The reaction mixture was stirred at 0°C for approximately 2 hours. Then, a saturated aqueous solution of sodium bicarbonate, dichloromethane (50 ml) were added to the reaction mixture at 0°C and stirred. The organic layer was washed with hydrochloric acid (1 M). The aqueous phase was combined and extracted with dichloromethane. Then the organic phase was collected, dried over sodium sulfate, and concentrated in vacuo.The products were isolated by column chromatography on silica gel (eluent with a gradient of 0% to 20% methanol in ethyl acetate). If necessary, the products were further purified by reverse-phase HPLC (eluent: water containing 0.05% trifluoroacetic acid; acetonitrile containing 0.05% trifluoroacetic acid).
[0258] The following were obtained as the output: (1 ,28,58)-H-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z28); (1B,28,58)-H-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(chlorodifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z38); (1,28,58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[-(trifluoroacetyl)-b-seryl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z48); (1K,28,58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-
[0259] (trifluoroacetyl)-E-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z58).
[0260] Yield: 13% for Z28; 11% for Z38; 18% for Z48; 16% for Z58. Products were identified by LCMS m / z 486.3 [M+H] + for Z28; 550.2 [M+H] + for Z38; 474.2 [M+H] + for Z48; 534.2 [M+H] + for Z58.
[0261] *N NMR (600 MHz, DMSO-de) for Z28 5 9.40 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 8.4 Hz, 1H), 7.67 (s, 1H), 4.98 (ddd, J = 11.1, 8.6, 5.1 Hz, 1H), 4.16 (s, 1H), 3.94 (dd, J = 10.5, 5.6 Hz, 1H), 3.84 (d, J = 6.9 Hz, 1H), 3.78 (s, 1H), 3.14 (t, J = 9.0, 1H), 3.05 (td, J = 9.3, 7.2 Hz, 1H), 2.40 -2.23 (m, 2H), 2.22 -2.00 (t, 2H), 1.78 - 1.62 (t, 2H), 1.59 (dd, J = 7.4, 5.6 Hz, 1H), 1.32 (d, J = 7.4 Hz, 1H), 1.04 - 0.86 (t, 12H).
[0262] 'H NMR (600 MHz, DMSO-dfi) for Z38 59.37 (d, J = 8.3 Hz, 1H), 9.02 (d, J = 8.5 Hz, 1H), 7.68 - 7.26 (t, 6H), 4.98 (ddd, J = 1, 8.1, 1, 1H), G.c. 4.20 (s, 1H), 4.08 - 4.05 (t, 1H), 3.89 (dd, J = 10.4, 5.5 Hz, 1H), 3.64 (s, 1H), 3.35 (dd, J = 12.1, 7.5 Hz, 1H), 3.35 (dd, J = 12.1, 7.5 Hz, 1H). Hz, 1H), 3.14 (t, J = 9.1, 1H), 3.05 (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2H), 1.57 (dd, J = 7.6, 5.4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 (s, 3H), 0.85 (s, 3H).
[0263] *H NMR (600 MHz, DMSO-de) for Z48 S 9.51 (d, J = 7.7 Hz, 1H), 8.94 (d, J = 8.1 Hz, 1H), 7.66 (s, 1H), 5.09 (ddd, J = 10.5, 8.0, 4.7 Hz, 4.7 Hz). (s, 1H), 4.03 - 3.80 (m, 4H), 3.84 (s, 1H), 3.17 (t, J = 8.2, 1H), 3.01 (td, J = 8.7, 6.9 Hz, 1H), 2.24 to 2.00 (m, 2H), 1.82 to 1.65 (m, 2H), 1.64 (dd, J = 7.1, 5.8 Hz, 1H), 1.39 (d, J = 6.8 Hz, 1H), 1.06 (s, 3H), 0.90 (s, 3H).
[0264] 'H NMR (600 MHz, DMSO-de) for Z58 8 9.37 (d, J = 8.3 Hz, 1H), 9.12 (d, J = 8.3 Hz, 1H), 7.68 - 7.26 (m, 6H), 4.98 (ddd, J = 1, 8.1, 1.7 Hz), 1H. 4.20 (s, 1H), 4.08 - 4.05 (m, 1H), 3.89 (dd, J = 10.4, 5.5 Hz, 1H), 3.64 (s, 1H), 3.35 (dd, J = 12.1, 7.5 Hz, 1H), 3.20 (dd, J = 12.1, 7.5 Hz, 1H). Hz, 1H), 3.14 (t, J = 9.1, 1H), 3.05 (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2H), 1.57 (dd, J = 7.6, 5.4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 (s, 3H), 0.85 (s, 3H).
[0265] As a result of the studies of the solvation ability of the obtained compounds Z28, Z38, Z48, Z58, under the conditions specified in Tables 3-6 for Z28, Z38, Z48, Z58, respectively, the following identification parameters were obtained for ( ,28,58)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-α-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z28) (Table 7); ( 1 R,2S,5S)-N-{(1 S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-
[0266] (chlorodifluoroacetyl)-T-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z38) (Table 8); (1I.,28.58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-|N-(trifluoroacetyl)-b-seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z48) (Table 9); ( ,28,58)-Н-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-
[0267] (trifluoroacetyl)-b-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z58) (Table 10).
[0268] Table 3-10 shows some of the positive results of the experiments, which resulted in the formation of new solvated forms of azabicyclohexane derivatives according to the present invention, obtained by the method indicated above. Negative results - solvated forms of azabicyclohexane derivatives were not formed, contrary to expectations - are not shown.
[0269] Table 3. Crystallization of new forms of (lR,2S,5S)-N-{(lS)-l-4HaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1 ,0]hexane-2-carboxamide (Z28).
[0270]
[0271] Table 6. Crystallization of new forms of (lR,2S,5S)-N-{(lS)-l-pHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[M-(trifluoroacetyl)-E-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z58).
[0272] In a similar manner to the above method, under the specified reaction conditions, other azabicyclohexane derivatives and their new solvated forms with an amount of solvating solvent from 0.5 to 3.0 according to the present invention were also obtained and identified according to the present invention.
[0273] The identification of substances obtained by the methods described above is presented below in Tables 7-10.
[0274] Table 7. Identification of solvation products of (1R,2S,5S)-N-{(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-T-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z28) by the methods of 'H, 13 With NMR, elemental analysis.
[0275] Table 8. Identification of the solvation products of (1R,2S,5S)-N-{(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(chlorodifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide (Z38) by the methods of 'H, 13 With NMR, elemental analysis.
[0276] Table 9. Identification of solvation products of (1R,2S,5S)-N-{(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z48) by methods 1 H, 13 With NMR, elemental analysis.
[0277] Table 10. Identification of solvation products of (1R,2S,5S)-N-{(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z58) by methods *H, 13 With NMR, elemental analysis.
[0278] Also prepared according to the syntheses disclosed in the prior art WO202 1250648 and studied by the methods used within the framework of the present invention were the compounds (1R,2S,5S)-N-{(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-3-[3-cyclobutyl-N-(trifluoroacetyl)-alanyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z68); (1,28,58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-(pyridin-2-yl)-(trifluoroacetyl)-T-alanyl]-3-azabicyclo[3.1,0]hexane-2-carboxamide ( 78); (1K,28,58)-M-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3 -( 1H-pyrazol-1-yl)-M-(trifluoroacetyl)-L-alanyl]-3-azabicyclo[3.1.0]hexan-
[0279] 2-carboxamide (Z88) (NMR spectra of compounds Z68, Z78, Z88 obtained in the course of the studies corresponded to the NMR spectra described in the prior art WO2021250648).
[0280] Thus, in the course of extensive recrystallization studies of (1R,2S,5S)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[H-(trifluoroacetyl)- -valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z28), (1R,2S,5S)-N-{(1S)-l-4HaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(chlorodifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z38), (1 R,2S,5 S)-N-{(1 S)- 1 - cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[M-(trifluoroacetyl)-b-seryl]-
[0281] 3-Azabicyclo[3.1.0]hexane-2-carboxamide (Z48), (lR,2S,5S)-N-{(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)- -phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (Z58), was found to be similar to ( 1 R,2S,5 S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3 -yl]ethyl]-3 -[(2S)-3 ,3-dimethyl-2- [(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide compounds Z28, Z38, Z48, Z58 form solvates with ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, methanol, ethanol, water, diethyl ether, dimethyl formamide, dimethyl sulfoxide, propyl acetate. In certain experiments, when using other solvents, contrary to expectations, the formation of solvates was not observed.
[0282] Within the framework of the present invention, according to the general schemes and synthetic approaches presented above, other azabicyclohexane derivatives and their new solvated forms according to the present invention were also prepared and studied.
[0283] Additionally, the physicochemical and technological properties of the solvates of the azabicyclohexane derivatives according to the present invention were studied (some results are presented below in the text). In a number of experiments, in addition to improving the solubility of the solvates of the azabicyclohexane derivatives according to the present invention, an improvement in stability and hygroscopicity was noted compared to the solvate of the azabicyclohexane derivative known in the prior art.
[0284] Example 2. Methods for the preparation of solvated forms of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline / amorphous forms
[0285] Below, particular embodiments of solvated forms of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, namely, the ethyl acetate and propyl acetate solvate, will be presented. In a similar manner, other solvated forms of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and its structural analogs according to the present invention were prepared and studied.
[0286] Ethyl acetate solvate of (1 ,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline form. The calculated amount of commercially available (lR,2S,5S)-N-[(lS)-l-IIHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of acetonitrile and ethyl acetate at a weight ratio of 1:8 - 1:15, respectively, at 20 - 25 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 - 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting solid precipitate was then filtered.The resulting crystalline powder was dried under reduced pressure of 1 - 90 mbar at a temperature of 20 - 50 °C for 30 minutes to 10 hours.
[0287] In particular, (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of acetonitrile and ethyl acetate (5 ml) at a weight ratio of 1:13, respectively, at 25 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. The formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The solid was then filtered. The resulting powder was dried at a reduced pressure of 40 mbar at a temperature of 20 °C for 2 hours.
[0288] Ethyl acetate solvate of (K,28,58)-1\-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in amorphous form. The calculated amount of commercially available (lR,2S,5S)-N-[(lS)-l-nHaHO-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of acetonitrile and ethyl acetate at a weight ratio of 1:1 - 1:10, respectively, at 25 - 30 °C. After complete dissolution, toluene was added 20 - 45% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 8 - 13 °C with a concomitant decrease in pressure to 0.1 atm and sonicated. Formation of solid particles was observed. Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 0.5 - 3.0 hours. The resulting sediment was then filtered.The obtained powder was dried by the fluidized bed drying method at a temperature of 30-40 °C. In particular, (1 .,28,58)-Ы-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of acetonitrile and ethyl acetate (5 ml at a weight ratio of 1:9, respectively) at 30 °C. After complete dissolution, 40% of toluene was added to the total volume of the mixture, the temperature of the mixture was sharply reduced to 9 °C with a concomitant decrease in pressure to 0.1 atm and processed with ultrasound. Formation of solid particles was observed. Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 0.5 hours. Then the resulting sediment was filtered. The resulting powder was dried using the fluidized bed drying method at a temperature of 35 °C.
[0289] Propyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline form. A calculated amount of commercially available (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of dioxane and propyl acetate at a weight ratio of 1:1 - 1:10, respectively, at 20 - 25 °C. After complete dissolution, the temperature of the mixture was gradually lowered to 10 - 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting solid precipitate was then filtered.The resulting crystalline powder was dried by drying in a fluidized bed at a temperature of 40 - 50 °C for 30 minutes to 10 hours.
[0290] In particular, ( 1 R,2S ,5 S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of dioxane and propyl acetate (5 ml) at a weight ratio of 1:9, respectively, at 25 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. Then the temperature was gradually raised to 20 °C and kept at a constant temperature for 2.5 hours. The solid was then filtered. The resulting powder was dried by the fluidized bed drying method at 40 °C for 2 hours. (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide propyl acetate solvate in amorphous form.The calculated amount of commercially available (^,28,58)-8[-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (NMR of commercially available (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- (trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide corresponded to the NMR ( ,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (CAS: 2628280-40-8)) was dissolved in a mixture of dioxane and propyl acetate at a weight ratio of 1:5 - 1:10, respectively, at 25 - 30 °C. After complete dissolution, toluene was added at 20-45% of the total volume of the mixture, the temperature of the mixture was sharply reduced to 8-15 °C with a concomitant reduction in pressure to 0.1 atm and processed with ultrasound. The formation of solid particles was observed.Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting sediment was then filtered. The resulting powder was dried using a fluidized bed drying method at a temperature of 30 - 40 °C.
[0291] In particular, (1 R,2S,5 S)-N-[(IS)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of dioxane and propyl acetate (10 ml at a weight ratio of 1:7, respectively) at 30 °C. After complete dissolution, toluene was added 30% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 10 °C with a concomitant decrease in pressure to 0.1 atm and treated with ultrasound. The formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 2.0 hours. The resulting sediment was then filtered. The resulting powder was dried using a fluidized bed drying method at a temperature of 40 °C.
[0292] Butyl acetate solvate (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo [3.1.0]hexane-2-carboxamide in crystalline form. The calculated amount of commercially available (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of heptane and butyl acetate at a weight ratio of 1:10 - 1:1, respectively, at 20 - 45 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 - 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. The temperature was then gradually increased to 20°C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting solid precipitate was then filtered.The resulting crystalline powder was dried under reduced pressure of 1 - 90 mbar at a temperature of 40 - 50 °C for 30 minutes to 10 hours.
[0293] In particular, (1 .,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of heptane and butyl acetate (5 ml) at a weight ratio of 1:10, respectively, at 45°C. After complete dissolution, the temperature of the mixture was gradually decreased to 15°C at a rate of 1°C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. Then the temperature was gradually brought to 20°C and maintained at a constant temperature for 3.0 hours. The resulting solid precipitate was then filtered. The resulting crystalline powder was dried under reduced pressure of 10 mbar at a temperature of 40 °C for 2 hours.
[0294] Butyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-unaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in amorphous form. The calculated amount of commercially available (1P,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of diethyl ether and butyl acetate at a weight ratio of 1:1 - 1:15, respectively, at 20 - 35 °C. After complete dissolution, toluene was added 20 - 45% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 8 - 12 °C with a concomitant decrease in pressure to 0.1 atm and treated with ultrasound. Formation of solid particles was observed. Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting sediment was then filtered.The obtained powder was dried by the fluidized bed drying method at 30-40 °C. In particular, (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of diethyl ether and butyl acetate (5 ml at a weight ratio of 1:5, respectively) at 35 °C. After complete dissolution, 40% of toluene was added to the total volume of the mixture, the temperature of the mixture was sharply reduced to 10 °C with a concomitant decrease in pressure to 0.1 atm and processed with ultrasound. Formation of solid particles was observed. Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 3.0 hours. Then the resulting sediment was filtered. The resulting powder was dried by drying in a fluidized bed at 40 °C.
[0295] Isobutyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in crystalline form. The calculated amount of commercially available (1K,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of heptane and isobutyl acetate at a weight ratio of 1:10 - 1:1, respectively, at 20 - 25 °C. After complete dissolution, the temperature of the mixture was gradually lowered to 10 - 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. The temperature was then gradually increased to 20°C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting solid precipitate was then filtered.The resulting crystalline powder was dried under reduced pressure of 1 - 90 mbar at a temperature of 40 - 50 °C for 30 minutes to 10 hours.
[0296] In particular, (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of heptane and isobutyl acetate (5 ml) at a weight ratio of 1:10, respectively, at 25°C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. Then the temperature was gradually raised to 20°C and kept at a constant temperature for 1.5-3.0 h. Then the solid was filtered. The resulting crystalline powder was dried under reduced pressure of 15 mbar at 45°C for 1.5 h. (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide isobutyl acetate solvate in amorphous form.The calculated amount of commercially available (1,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of diethyl ether and isobutyl acetate at a weight ratio of 1:1 - 1:15, respectively, at 20 - 25 °C. After complete dissolution, toluene was added 20 - 45% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 8 - 12 °C with a concomitant decrease in pressure to 0.1 atm and treated with ultrasound. Formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The solid was then filtered. The resulting powder was dried using a fluidized bed drying method at 30 - 40 °C.
[0297] In particular, (1B,28,58)-Ы-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of diethyl ether and isobutyl acetate (5 ml at a weight ratio of 1:6, respectively) at 25 °C. After complete dissolution, toluene was added 35% of the total volume of the mixture, the temperature of the mixture was sharply reduced to 11 °C with a concomitant decrease in pressure to 0.1 atm and treated with ultrasound. The formation of solid particles was observed. The temperature was then gradually raised to 20 °C and maintained at a constant temperature for 2.0 hours. The solid was then filtered. The resulting powder was dried using a fluidized bed drying method at 40 °C.
[0298] Tetrahydrofuran solvate of (lR,2S,5S)-N-[(lS)-l-4HaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl | -6, 6-dimethyl-3-azabipylic o [3.1.0] hexane-2-carboxamide in crystalline form. The calculated amount of commercially available (P1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of dioxane and tetrahydrofuran at a weight ratio of 1 : 1 - 1 : 8, respectively, at 20 - 35 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 - 15 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The resulting solid precipitate was then filtered.The resulting crystalline powder was dried by drying in a fluidized bed at a temperature of 40 - 50 °C for 30 minutes to 10 hours.
[0299] In particular, (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of dioxane and tetrahydrofuran (at a weight ratio of 1:7, respectively) at 35 °C. After complete dissolution, the temperature of the mixture was gradually decreased to 10 °C at a rate of 1 °C / hour with a concomitant decrease in pressure to 0.1 atm under stirring. Formation of solid particles was observed. Then the temperature was gradually brought to 20 °C and maintained at a constant temperature for 1.5 hours. The solid was then filtered. The resulting powder was dried using fluidized bed drying at 45°C for 2 hours.
[0300] Tetrahydrofuran solvate of (lR,2S,5S)-N-[(lS)-l-nnaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in amorphous form. The calculated amount of commercially available (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide was dissolved in a mixture of dioxane and tetrahydrofuran at a weight ratio of 1:4 - 1:8, respectively, at 25 - 35 °C. After complete dissolution, toluene was added 20 - 45% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 8 - 15 °C with a concomitant decrease in pressure to 0.1 atm and sonicated. Formation of solid particles was observed. The temperature was then gradually increased to 20 °C and maintained at a constant temperature for 1.5 - 3.0 hours. The solid was then filtered.The resulting powder was dried using a fluidized bed drying method at a temperature of 30–40 °C.
[0301] In particular, (1K,28,58)- -[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3- [(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (50 mg) was dissolved in a mixture of dioxane and tetrahydrofuran (5 ml, weight ratio 1:7, respectively) at 35 °C. After complete dissolution, toluene was added 35% of the total volume of the mixture, the temperature of the mixture was sharply decreased to 11 °C with a concomitant decrease in pressure to 0.1 atm and sonicated. The formation of solid particles was observed. The temperature was then gradually raised to 20 °C and maintained at a constant temperature for 1.5 hours. The solid was then filtered. The resulting powder was dried using a fluidized bed drying method at 35 °C.
[0302] Identification of the obtained products was carried out using the following analytical methods: !H NMR, 13 With NMR spectroscopy, elemental analysis, powder X-ray diffraction, single crystal X-ray diffraction, DSC (differential scanning calorimetry) and TGA (thermogravimetric analysis).
[0303] Based on the results of the analyses, it was possible to establish the qualitative and phase compositions of the solvates of (1R,2S,5S)-N-[(1S)- 1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline / amorphous forms obtained by the methods described above. The results of the analyses are presented below.
[0304] The above methods of production have been adapted for industrial production.
[0305] Ethyl acetate solvate (1K,28,58)-M-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide (1 : 1):
[0306] -crystalline form:
[0307] >H NMR (600 MHz, DMSO-ds) 5 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 4, 8.6 G = 8.4 Hz, 1H), 4.16 (s, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, lH), 3.70 (d, J = 10.4 Hz, 1H (1. 4), 1. , 3.1. (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 1.78 ( dd = 1.5, 1.6). 7.6, 5.4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.17 (t, J = 7.1 Hz, 3H), 1.03 (s, 3H), 0.98 (s, 9H), 0.85 (s, 3H).
[0308] I3 C NMR (151 MHz, DM SO -of) 5 177.5, 170.7, 170.3, 167.5, 157.2, 156.8, 119.6, 118.8, 116.9, 115.7, 513.1, 160.1. 47.6, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 20.7, 18.9, 14.4, 12.3.
[0309] Elemental analysis of C23H32F3N5O4 C4H8O2: calculated C 55.19%, H 6.86%, N 11.92%, O 16.34%; found C 55.24%, H 6.89%, N 11.84%, and O 16.39%.
[0310] -amorphous form:
[0311] *H NMR (600 MHz, DMSO-ds) S 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 10.9, 8.6, 5.1 Hz, J = 4.2 Hz), J 8.4 Hz, 1H), 4.16 (s, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (d, J = 10.4 Hz, lH), 3.14 (t, J = 1, 159). (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 5.4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.17 (t, J = 7.1 Hz, 3H), 1.03 (s, 3H), 0.98 (s, 9H), 0.85 (s, 3H).
[0312] 13 C NMR (151 MHz, in DMSO) 8 177.5, 170.7, 170.3, 167.5, 157.2, 156.8, 119.6, 118.8, 116.9, 115.0, 113.1, 60.1, 59.7, 59.7. 47.6, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 20.7, 18.9, 14.4, 12.3.
[0313] Elemental analysis C33H32P3^O C H2O2: calculated C 55.19%, H 6.86%, N 11.92%, O 16.34%; found C 55.27%, H 6.90%, N 11.89%, O 16.41%. (1 ,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, propyl acetate solvate (1:1):
[0314] -crystalline form:
[0315] 'H NMR (600 MHz, DMSO-de) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 10.9, 8.6, 5.1 Hz, 1H), 4.42 (d, J = 8.4 Hz, 1H), 4.16 (s, 1H), 3.98 (t, J = 6.9 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (s, 1H), 3.14 (t, J = 9.1, 1H), 3.05 (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 -2.04 (m, 2H), 2.02 (s, 3H), 1.78 - 1.62 (m, 4H), 1.57 (dd, J = 7.6, 5.4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 - 0.83 (m, 18H).
[0316] 13C NMR (151 MHz, of DMSO) 8 177.5, 170.7, 169.4, 167.4, 157.1, 156.8, 119.5, 118.8, 116.7, 115.0,
[0317] 113.1, 65.7, 60.1, 58.2, 47.6, 39.2, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 1.2.5, 9.2.
[0318] Elemental analysis C23H32F3N5O4 C5H10O2: calculated C 55.90%, H 7.04%, N 11.64%, O 15.95%; found C 55.81%, H 7.16%, N 11.78%, and O 15.81%.
[0319] -amorphous form:
[0320] 'H NMR (600 MHz, of DMSO) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 5, 2.6 G = 8.4 Hz, 1H), 4.16 (s, 1H), 3.98 (t, J = 6.9 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (s, 1H), 3.14 (t, 3, J0 = 9). 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 −2.04 (m, 2H), 2.02 (s, 3H), 1.78 − 1.72.6, J (m, = 4 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 - 0.83 (m, 18H).
[0321] 13C NMR (151 MHz, DMSO-de) 8 177.5, 170.7, 169.4, 167.4, 157.1, 156.8, 119.5, 118.8, 116.7, 115.0,
[0322] 113.1, 65.7, 60.1, 58.2, 47.6, 39.2, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 22.4, 20.5, 18.9, 12.3, 9.2.
[0323] Elemental analysis of C23H32F3N5O4 C5H10O2: calculated C 55.90%, H 7.04%, N 11.64%, O 15.95%; found C 55.76%, H 7.14%, N 11.52%, O 15.86%.
[0324] Butyl acetate solvate (1K,28.58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1 ,0]hexane-2-carboxamide (1 : 1):
[0325] -crystalline form:
[0326] *H NMR (600 MHz, of DMSO) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 5, 2.6 G = 8.4 Hz, 1H), 4.16 (s, 1H), 4.04 (t, J = 6.6 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (d, J = 10.4 Hz, J. 1 5 (H). 3, 3. (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 1.78 (dd = 1.5, 1.2). 7.6, 5.5 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.04- 0.82 (m, 18H).
[0327] 13 C NMR (151 MHz, of DMSO) 8 177.5, 170.7, 170.2, 167.5, 157.2, 156.8, 119.6, 118.8, 116.9, 115.0,
[0328] 113.1, 63.4, 60.1, 58.2, 47.6, 37.8, 36.7, 34.6, 34.2, 30.3, 30.2, 27.3, 26.9, 26.3, 25.7, 18.9, 18.7. 12.3.
[0329] Elemental analysis of C23H32F3N5O4 C6H12O2: calculated C 56.57%, H 7.20%, N 11.37%, O 15.59%; found C 56.50%, H 7.26 %, N 11.32%, and O 15.51%.
[0330] -amorphous form:
[0331] *H NMR (600 MHz, of DMSO) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 5, 2.6 G = 8.4 Hz, 1H), 4.16 (s, 1H), 4.04 (t, J = 6.6 Hz, 2H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (d, J = 10.4 Hz, J. 1 5 (H). 3, 3. (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 1.78 (dd = 1.5, 1.2). 7.6, 5.5 Hz, 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.04 to 0.82 (m, 18H).
[0332] 13 C NMR (151 MHz, of DMSO) S 177.5, 170.7, 170.2, 167.5, 157.2, 156.8, 119.6, 118.8, 116.9, 115.0,
[0333] 113.1, 63.4, 60.1, 58.2, 47.6, 37.8, 36.7, 34.6, 34.2, 30.3, 30.2, 27.3, 26.9, 26.3, 25.7, 18.9, 18.7. 12.3.
[0334] Elemental analysis of C23H32F3N5O4 C6H12O2: calculated C 56.57%, H 7.20 %, N 1 1.37%, O 15.59%; found C 56.48%, H 7.31 %, N 11.30%, and O 15.47%.
[0335] Isobutyl acetate solvate (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1):
[0336] -crystalline form:
[0337] 'H NMR (600 MHz, of DMSO) 5 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1 H), 5.00 (ddd, J = 1.4, 4, 2.6 H = 8.4 Hz, 1H), 4.16 (s, 1H), 3.95 - 3.78 (m, 3H), 3.70 (s, 1H), 3.14 (t, J = 9.1, 1H), 3.05 (td, J = 9.4, 4. 7.1 (t0, Hz), 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 1.98 - 1.62 (m, 3H), 1.57 (dd, J = 7.6, 5.4 Hz, 1.6 (D), J = 1.3), H (s, 3H), 0.99 - 0.88 (s, 15H), 0.85 (s, 3H).
[0338] 13 C NMR (151 MHz, of DMSO) 8 177.5, 171.6, 170.7, 167.5, 157.4, 156.5, 119.7, 118.8, 116.9, 115.0,
[0339] 113.1, 71.3, 60.3, 58.1, 47.7, 39.2, 37.7, 36.7, 34.6, 34.2, 30.3, 28.0, 27.3, 26.8, 27.3, 19.6, 25.7. 12.3.
[0340] Elemental analysis CzaHsiFsNjC -CeHizOz: calculated C 56.57%, H 7.20%, N 11.37%, O 15.59%; found C 56.68%, H 7.14 %, N 11.28%, and O 15.53%.
[0341] -amorphous form:
[0342] *H NMR (600 MHz, DMSO-do) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 5, 2.6 H = 8.4 Hz, 1H), 4.16 (s, 1H), 3.95 - 3.78 (m, 3H), 3.70 (s, 1H), 3.14 (t, J = 9.1, 1H), 3.05 (td, J = 9.4, 4. 1 =H 0, Hz 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.99 (s, 3H), 1.98 - 1.62 (m, 3H), 1.57 (dd, J = 7.6, 5.4 Hz, 1.6 (D), J = 1.3), H (s, 3H), 0.99 - 0.88 (s, 15H), 0.85 (s, 3H).
[0343] 13 C NMR (151 MHz, of DMSO) 8 177.5, 171.6, 170.7, 167.5, 157.4, 156.5, 119.7, 118.8, 116.9, 115.0,
[0344] 113.1, 71.3, 60.3, 58.1, 47.7, 39.2, 37.7, 36.7, 34.6, 34.2, 30.3, 28.0, 27.3, 26.8, 26.3, 25.7, 21.6, 19.0, 18.7, 12.3.
[0345] Elemental analysis of C23H32F3N5O4 C6H12O2: calculated C 56.57%, H 7.20%, N 11.37%, O 15.59%; found C 56.63%, H 7.26 %, N 11.40%, O 15.48%.
[0346] Tetrahydrofuran solvate (1 R,2S,5 S)-N-[(1 S)- 1-cyano-2-[(3 S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1):
[0347] -crystalline form:
[0348] 'H NMR (600 MHz, of DMSO) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 1.4, 4, 2.6 G = 8.4 Hz, 1H), 4.16 (s, 1H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (d, J = 10.4 Hz, 1H), 3.68 − 0.55 (m, 4H), 3.1 = 1 (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.83 - 1.62 (m, 5.5. 6H), Гdd = 1, 1. 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 (s, 3H), 0.98 (s, 9H), 0.85 (s, 3H). 13 C NMR (151 MHz, DMSO-ck) 5 177.5, 170.7, 167.4, 157.1, 156.8, 1 19.5, 118.8, 116.7, 115.0, 113.1, 4 606.1, 39.2, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 25.1, 18.9, 12.3.
[0349] Elemental analysis C23H32F3N5O4 C4H8O: calculated C 56.73%, H 7.05%, N 12.25%, O 13.99%; found C 56.61%, H 7.20%, N 12.39%, and O 13.82%.
[0350] -amorphous form:
[0351] 'H NMR (600 MHz, DMSO-db) 8 9.43 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 5.00 (ddd, J = 10.4.4, 5.1 H J = 8.4 Hz, 1H), 4.16 (s, 1H), 3.90 (dd, J = 10.4, 5.5 Hz, 1H), 3.70 (d, J = 10.4 Hz, 1H), 3.68 - 3.55 (m, 1 49), J. 3, 3.3. (td, J = 9.4, 7.1 Hz, 1H), 2.40 (tdd, J = 10.4, 8.4, 4.4 Hz, 1H), 2.22 - 2.00 (m, 2H), 1.83 - 1.62 (m, 5.5. 6H), Гdd = 1, 1. 1H), 1.32 (d, J = 7.6 Hz, 1H), 1.03 (s, 3H), 0.98 (s, 9H), 0.85 (s, 3H).
[0352] ,3 C NMR (151 MHz, DM SO -de) 8 177.5, 170.7, 167.4, 157.1, 156.8, 1 19.5, 118.8, 116.7, 115.2, 113.1, 5 39.2, 37.8, 36.7, 34.6, 34.2, 30.3, 27.3, 26.9, 26.3, 25.7, 25.1, 18.9, 12.3.
[0353] Elemental analysis C23H32F3N5O4 C4H8O: calculated C 56.73%, H 7.05%, N 12.25%, O 13.99%; found C 56.61%, H 7.20%, N 12.39%, and O 13.82%.
[0354] The DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min). The results of studying the ethyl acetate solvate of (1R,2S,5S)- K-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline form are shown in Fig. 1.1. When studying the sample by DSC, an endothermic peak was recorded, which is highly likely related to the desorption of the crystallization solvent in the region of 90 °C, and a subsequent change in the crystal lattice. Presumably, after desolvation, the sample is transformed into an amorphous phase. The TGA method also allowed us to record a loss of sample mass in the region of 90 °C, caused by desorption of the crystallization solvent.
[0355] The results of the study of the propyl acetate solvate of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline form are shown in Fig. 1.2. When studying the sample by DSC, an endothermic peak was recorded, which is highly likely related to the desorption of the crystallization solvent in the region of 100 °C, and the subsequent change in the crystal lattice. Presumably, after desolvation, the sample is transformed into an amorphous phase. The TGA method also made it possible to record the loss of sample mass in the region of 100 °C due to the desorption of the crystallization solvent.
[0356] The results of the study of the butyl acetate solvate of (1R,2S,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline form are shown in Fig. 1.3. When studying the sample by DSC, an endothermic peak was recorded, which is highly likely related to the desorption of the crystallization solvent in the region of 100 °C, and a subsequent change in the crystal lattice. Presumably, after desolvation, the sample is transformed into an amorphous phase. The TGA method also made it possible to record the loss of sample mass in the region of 100 °C due to the desorption of the crystallization solvent.
[0357] The results of the studies of the isobutyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline form are shown in Fig. 1.4. When studying the sample by DSC, an endothermic peak was recorded, which is highly likely related to the desorption of the crystallization solvent in the region of 100 °C, and a subsequent change in the crystal lattice. Presumably, after desolvation, the sample is transformed into an amorphous phase. The TGA method also made it possible to record the loss of sample mass in the region of 100 °C due to the desorption of the crystallization solvent.
[0358] The results of the study of tetrahydrofuran solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline form are shown in Fig. 1.5. When studying the sample by DSC, an endothermic peak was recorded, which is highly likely related to the desorption of the crystallization solvent in the region of 80 °C, and a subsequent change in the crystal lattice. Presumably, after desolvation, the sample is transformed into an amorphous phase. The TGA method also allowed recording the loss of sample mass in the region of 80 °C due to desorption of the crystallization solvent.
[0359] The diffraction pattern of the ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1) in amorphous form (Fig. 2.1) clearly shows a maximum in the form of a halo in the angular region of 6.00 - 28.00 20 (± 2.00°). DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min). The DSC / TGA curves demonstrated a phase transition characteristic of the desolvation process. The X-ray diffraction pattern of the propyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1) in amorphous form (Fig. 2.2) clearly shows a halo-like maximum in the angular range of 6.00 - 28.00 20 (± 2.00°). DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min).The DSC / TGA curves showed a phase transition characteristic of the desolvation process.
[0360] The diffraction pattern of the butyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)- 2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in amorphous form (Fig. 2.3) clearly shows a maximum in the form of a halo in the region of angles 8 - 30 20 (± 2°). DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min). The DSC / TGA curves showed a phase transition characteristic of the desolvation process.
[0361] The diffraction pattern of the isobutyl acetate solvate of (IК,28,58)-Н-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in amorphous form (Fig. 2.4) clearly shows a maximum in the form of a halo in the region of angles 9-26 20 (± 2°). DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min). The DSC / TGA curves showed a phase transition characteristic of the desolvation process.
[0362] The diffraction pattern of tetrahydrofuran solvate of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in amorphous form (Fig. 2.5) clearly shows a maximum in the form of a halo in the angular region of 6.00 - 27.00 20 (± 2°). DSC and TGA experiments were carried out in the following mode: heating to 300 °C (10 deg / min) in an air flow (250 ml / min). The DSC / TGA curves showed a phase transition characteristic of the desolvation process.
[0363] Single crystal X-ray diffraction data made it possible to accurately determine such characteristics of the crystal of ethyl acetate solvate (lR,2S,5S)-N-[(lS)-l-UHaHo-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) as: syngony, space group and cell parameters (Table 11), as well as fractional coordinates of atoms, equivalent thermal parameters (Table 12) and the arrangement of molecules in the unit cell (Fig. 3.1). The analysis was carried out at a temperature of 100 K, which corresponds to - 173.15 °C.
[0364] Table 11. Unit cell parameters of the crystalline form of the ethyl acetate solvate of (1,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]- 3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide.
[0365] *- where each of the parameters represents the length of one of the edges a, b or c.
[0366] **- where each of the parameters represents one of the angles between the edges a, 0 or y.
[0367] Table 12. Fractional coordinates of atoms and equivalent thermal parameters of the unit cell of U eq ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0368] ATOM X y Z Ueq
[0369] Fl 7012(3) 191(4) 7700.3(18) 44.9(8)
[0370] F2 8029(3) -145(4) 9184.2(19) 42.1(8)
[0371] F3 8429(3) 1627(4) 8366(2) 50.9(9)
[0372] 01 3212(3) 7824(4) 3571.4(19) 29.8(8) Atom
[0373] 02 2715(3) 7214(4) 7218.6(19) 27.4(7)
[0374] 03 4477(3) 4504(4) 6725.2(18) 27.8(7)
[0375] 04 6807(3) 1913(4) 9619(2) 36.7(9)
[0376] N1 4352(3) 9528(5) 4653(2) 26.8(8)
[0377] N2 1631(3) 6188(4) 5793(2) 20.7(8)
[0378] N3 3687(3) 4338(4) 7844(2) 20.3(7)
[0379] N4 6368(3) 3086(4) 8161(2) 21.9(8)
[0380] N5 -969(3) 7185(5) 4519(3) 34.0(10)
[0381] Cl 2970(4) 8386(5) 5095(3) 23.2(9)
[0382] C2 3410(4) 9778(5) 5729(3) 26.3(10)
[0383] C3 4516(4) 10144(6) 5611(3) 31.7(11)
[0384] C4 3497(4) 8540(5) 4334(3) 22.7(9)
[0385] C5 1706(4) 8195(5) 4629(3) 23.6(9)
[0386] C6 1183(4) 7641(5) 5352(3) 22.4(9)
[0387] C7 2348(4) 6110(5) 6718(3) 20.4(9)
[0388] C8 2583(3) 4468(5) 7100(3) 21.4(9)
[0389] C9 1775(4) 4075(5) 7596(3) 22.4(9)
[0390] CIO 2439(4) 3918(5) 8663(3) 23.3(9)
[0391] Cl l 3646(4) 4205(5) 8824(3) 23.7(9)
[0392] C12 1848(4) 2535(5) 8080(3) 23.3(9)
[0393] C13 4582(4) 4399(5) 7586(3) 22.2(9)
[0394] C14 5734(4) 4329(5) 8376(3) 22.7(9)
[0395] C15 6362(4) 5889(5) 8521(3) 26.3(10)
[0396] C16 6858(4) 2036(6) 8823(3) 25.6(10)
[0397] C17 7586(4) 919(6) 8515(3) 29.9(10)
[0398] C18 7466(4) 5720(7) 9368(3) 36.6(12)
[0399] C19 6610(4) 6386(6) 7633(3) 32.5(11)
[0400] C20 5651(4) 7105(6) 8769(4) 37.4(12)
[0401] C21 773(4) 2089(6) 8208(3) 30.7(10)
[0402] C22 2481(4) 1232(5) 7865(3) 29.6(10)
[0403] C23 -36(4) 7419(5) 4875(3) 26.5(10) Atom x y Z Ueq
[0404] O1S 771(3) 4605(4) 3903(2) 35.5(8)
[0405] O2S 1116(3) 2916(4) 2922(2) 37.2(9)
[0406] CIS 1430(4) 3841(6) 3675(3) 30.6(11)
[0407] C2S 2666(4) 3847(7) 4207(3) 38.3(12)
[0408] C3S -69(4) 2839(7) 2357(3) 39.3(12)
[0409] C4S -208(5) 2054(9) 1430(4) 57.9(18)
[0410] Single crystal X-ray diffraction data made it possible to accurately determine such characteristics of the crystal of propyl acetate solvate of (1,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), such as: syngony, space group and cell parameters (Table 13), as well as fractional coordinates of atoms, equivalent thermal parameters (Table 14) and the arrangement of molecules in the unit cell (Fig. 3.2). The analysis was carried out at a temperature of 140 K, which corresponds to - 133.15 °C.
[0411] Table 13. Unit cell parameters of the crystalline form of propyl acetate solvate of (1,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2, 2, 2-trifluoroacetyl)amino]butanoyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0412] *- where each of the parameters represents the length of one of the edges a, b or c.
[0413] **- where each of the parameters represents one of the angles between the edges a, 0 or y.
[0414] Table 14. Fractional coordinates of atoms and equivalent thermal parameters of the unit cell Ueq of propyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0415] Atom x y
[0416] F1 3453.5(10) 209.3(13) 2409.3(7) 38.6(3)
[0417] <h2 style=";text-align:left;direction:ltr">F2 2573.2(9) -125.6(13) 956.2(7) 38.0(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0418] <h2 style=";text-align:left;direction:ltr"> F3 2065.1(9) 1564.9(14) 1806.7(9) 40.9(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0419] <h2 style=";text-align:left;direction:ltr"> 01 6575.6(11) 7821.8(16) 6367.3(8) 33.8(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0420] <h2 style=";text-align:left;direction:ltr"> 02 7622.8(10) 7149.0(14) 2751.2(8) 26.9(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0421] <h2 style=";text-align:left;direction:ltr"> ОЗ 5751.2(8) 4602.3(15) 3304.9(7) 25.0(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0422] <h2 style=";text-align:left;direction:ltr"> 04 3803.6(13) 1930.9(19) 492.7(9) 48.0(4)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0423] <h2 style=";text-align:left;direction:ltr"> N1 5614.2(10) 9525.1(19) 5303.1(9) 26.9(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0424] <h2 style=";text-align:left;direction:ltr"> N2 8469.2(10) 6148.5(16) 4182.9(9) 19.2(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0425] <h2 style=";text-align:left;direction:ltr"> N3 6655.3(9) 4327.1(15) 2173.9(8) 17.2(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0426] <h2 style=";text-align:left;direction:ltr"> N4 4028.9(10) 3153.9(16) 1914.5(9) 19.4(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0427] <h2 style=";text-align:left;direction:ltr"> N5 10896.9(12) 7190(2) 5462.3(11) 36.8(4)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0428] <h2 style=";text-align:left;direction:ltr"> C1 7025.7(13) 8332(2) 4860.0(11) 21.4(3)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0429] <h2 style=";text-align:left;direction:ltr"> С2 6680.0(14) 9695(2) 4211.1(12) 28.1(4)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0430] <h2 style=";text-align:left;direction:ltr"> СЗ 5563.9(14) 10096(3) 4348.2(12) 34.5(5)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0431] <h2 style=";text-align:left;direction:ltr"> C4 6394.3(13) 8518.6(19) 5609.2(11) 22.6(3)<h2 style=";text-align:left;direction:ltr">
[0432] C5 8223.6(13) 8144(2) 5321.0(10) 21.6(3)
[0433] C6 8850.6(12) 7585.3(19) 4614.5(11) 20.2(3)
[0434] C7 7888.4(12) 6058.2(19) 3260.0(10) 19.2(3)
[0435] C8 7682.6(11) 4440.4(19) 2893.1(10) 17.8(3)
[0436] S9 8530.1(12) 4043(2) 2369.2(10) 20.9(3)
[0437] SY 7969.7(13) 3856(2) 1321.4(11) 21.7(3)
[0438] SP 6780.3(12) 4134(2) 1189.7(10) 21.1(3)
[0439] C12 8504.1(14) 2527(2) 1899.8(11) 25.3(4) Atom x
[0440] C13 5735.0(11) 4445.6(18) 2451.5(10) 17.5(3)
[0441] C14 4678.1(11) 4379.9(19) 1676.9(10) 18.8(3)
[0442] C15 3647.2(13) 2073(2) 1283.4(11) 23.6(3)
[0443] C16 2926.9(13) 924(2) 1618.8(11) 25.8(4)
[0444] C17 4066.6(12) 5907(2) 1530.8(11) 22.0(3)
[0445] C18 4821.7(15) 7115(2) 1320.4(14) 32.0(4)
[0446] С19 3101.3(15) 5741(2) 660.7(13) 35.6(4)
[0447] С20 3652.1(15) 6354(2) 2391.2(13) 30.1(4)
[0448] С21 7864.8(16) 1240(2) 2156.4(13) 32.4(4)
[0449] С22 9577.2(16) 2075(3) 1712.7(14) 37.5(5)
[0450] С23 10007.8(14) 7387(2) 5099.3(11) 24.8(4)
[0451] O1S 9025.6(11) 4632.1(16) 6081.5(9) 36.4(3)
[0452] O2S 8602.2(11) 2872.5(18) 7025.3(9) 37.4(3)
[0453] CIS 7220.4(16) 3682(3) 5720.9(14) 45.5(6)
[0454] C2S 8371.5(15) 3792(2) 6274.4(12) 30.2(4)
[0455] C3S 9682.9(16) 2976(3) 7642.6(14) 41.4(5)
[0456] C4S 9702.0(19) 2212(4) 8565.6(16) 52.3(6)
[0457] C5S 10784(2) 2452(4) 9279.6(17) 60.4(7)
[0458] Single crystal X-ray diffraction data made it possible to accurately determine such characteristics of the crystal of butyl acetate solvate (lR,2S,5S)-N-[(lS)-l-UHaHo-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), such as: syngony, space group and cell parameters (Table 15), as well as fractional coordinates of atoms, equivalent thermal parameters (Table 16) and the arrangement of molecules in the unit cell (Fig. 3.3). The analysis was carried out at a temperature of 100 K, which corresponds to - 173.15 °C.
[0459] Table 15. Unit cell parameters of the crystalline form of butyl acetate solvate of ( 1 R,2S,5 S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3 - yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0460] *- where each of the parameters represents the length of one of the edges a, b or c.
[0461] **- where each of the parameters represents one of the angles between the edges a, 0 or y.
[0462] Table 16. Fractional coordinates of atoms and equivalent thermal parameters of the unit cell U eq butyl acetate solvate of (1R,2S,5S)-N-[(1 S -1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1).
[0463] Atom U Z Ueq
[0464] F1 3329.3(18) 9740(2) 2335.5(13) 44.8(5)
[0465] F2 2483.9(16) 10067(2) 883.9(13) 42.7(5)
[0466] F3 2007.5(15) 8293(3) 1704.5(16) 48.2(6)
[0467] O1 6643.6(17) 2136(3) 6447.2(14) 34.2(5)
[0468] 02 7623.8(15) 2909(2) 2811.4(12) 26.4(4)
[0469] OZ 5687.8(13) 5434(2) 3297.7(11) 22.4(4)
[0470] 04 3728(2) 8007(3) 455.7(15) 43.2(6)
[0471] N1 5660.9(17) 460(3) 5357.1(15) 27.2(5)
[0472] N2 8409.9(16) 3940(3) 4239.3(14) 19.1(4)
[0473] N3 6602.7(15) 5719(3) 2219.1(12) 15.6(4)
[0474] N4 3993.4(16) 6792(3) 1874.8(14) 20.5(4)
[0475] N5 10824.8(19) 2913(4) 5485.3(18) 39.8(7)
[0476] S1 7036(2) 1700(3) 4933.5(17) 21.9(5) Atom x U Ueq
[0477] C2 6679(2) 332(4) 4276.4(19) 27.6(6)
[0478] SZ 5586(2) -71(4) 4396.3(19) 29.9(6)
[0479] C4 6441(2) 1472(3) 5684.7(18) 24.4(6)
[0480] C5 8217(2) 1899(3) 5382.4(17) 23.0(5)
[0481] C6 8805.2(19) 2476(3) 4671.1(17) 20.8(5)
[0482] C7 7853.5(18) 4033(3) 3320.4(16) 17.9(5)
[0483] C8 7599.0(17) 5677(3) 2964.3(15) 16.6(4)
[0484] C9 8422(2) 6221(3) 2483.6(17) 21.0(5)
[0485] IOC 7902(2) 6346(3) 1437.5(17) 21.9(5)
[0486] Cl l 6756.0(19) 5899(3) 1263.7(16) 19.7(5)
[0487] C12 8304(2) 7775(4) 2014.7(18) 27.5(6)
[0488] C13 5693.2(17) 5562(3) 2462.2(15) 16.5(4)
[0489] C14 4666.7(18) 5574(3) 1670.7(16) 19.4(5)
[0490] C15 4112.0(19) 3976(3) 1527.3(17) 21.6(5)
[0491] C16 3584(2) 7862(4) 1233.5(18) 24.7(5)
[0492] C17 2840(2) 8998(4) 1542(2) 30.3(6)
[0493] C18 4885(2) 2773(4) 1343(2) 29.0(6)
[0494] C19 3722(2) 3502(4) 2380(2) 27.0(6)
[0495] C20 3160(2) 4095(4) 654(2) 32.9(7)
[0496] C21 7566(3) 8991(4) 2204(2) 34.8(7)
[0497] C22 9329(3) 8433(5) 1895(2) 46.5(10)
[0498] C23 9947(2) 2692(4) 5137.1(18) 27.5(6)
[0499] O1S 8890(2) 5606(3) 6050.5(17) 50.7(7)
[0500] O2SA 8643(5) 7416(8) 6875(5) 32.7(8)
[0501] O2SB 8238(3) 7862(5) 6588(3) 32.7(8)
[0502] CIS 8207(4) 6466(4) 6146(2) 44.6(9)
[0503] C2S 7065(3) 6263(5) 5675(3) 50.6(10)
[0504] C3SA 9769(7) 7737(13) 7229(5) 43.5(13)
[0505] C3SB 9254(5) 8148(8) 7221(4) 43.5(13)
[0506] C4SA 9962(6) 8116(10) 8261(5) 45(2)
[0507] C4SB 9337(4) 7357(8) 8159(4) 38.7(13)
[0508] C5SA 9403(6) 9540(9) 8472(6) 39(2)
[0509] C5SB 10394(5) 7592(10) 8875(6) 59(2)
[0510] C6SA 9673(8) 9902(15) 9506(6) 56(3)
[0511] C6SB 10402(6) 6824(10) 9787(5) 66(2) Single crystal X-ray diffraction data made it possible to accurately determine the following characteristics of the crystal of isobutyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4HaHO- 2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1), such as: syngony, space group and cell parameters (Table 17), as well as fractional coordinates of atoms, equivalent thermal parameters (Table 18) and the arrangement of molecules in the unit cell (Fig. 3.4). The analysis was carried out at a temperature of 140 K, which corresponds to - 133.15 °C.
[0512] Table 17. Unit cell parameters of the crystalline form of isobutyl acetate solvate of (1B,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide.
[0513] *- where each of the parameters represents the length of one of the edges a, b or c.
[0514] **- where each of the parameters represents one of the angles between the edges a, 0 or y.
[0515] Table 18. Fractional coordinates of atoms and equivalent thermal parameters of the unit cell U eq isobutyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
[0516] (1:1).
[0517] Atom
[0518] Fl 6523.0(16) 9714(2) 7630.1(14) 47.9(6)
[0519] F2 7352.2(16) 10041(2) 9101.9(13) 48.0(6)
[0520] F3 7889.4(15) 8380(2) 8277.1(14) 46.5(5)
[0521] 01 3353.4(18) 2082(3) 3558.1(16) 46.0(6)
[0522] 02 2409.3(17) 2886(2) 7221.6(14) 32.7(5)
[0523] OZ 4275.0(15) 5364(2) 6679.1(13) 30.1(5)
[0524] 04 6090(2) 8043(3) 9495.6(17) 59.1(8)
[0525] N1 4352.7(19) 480(3) 4662.8(17) 35.1(7)
[0526] N2 1567.2(17) 3828(3) 5773.0(16) 23.3(6)
[0527] N3 3368.5(17) 5659(3) 7784.5(15) 21.3(5)
[0528] N4 5974.2(18) 6760(3) 8119.5(16) 24.3(6)
[0529] N5 -854(2) 2770(4) 4556(2) 46.3(8)
[0530] Cl 2963(2) 1661(4) 5088(2) 27.4(7)
[0531] C2 3335(2) 339(4) 5759(2) 34.6(8) sz 4433(3) -34(5) 5630(2) 43.0(9)
[0532] C4 3561(3) 1445(4) 4337(2) 31.8(8)
[0533] C5 1782(2) 1825(4) 4639(2) 29.1(7)
[0534] C6 1181(2) 2401(3) 5352(2) 25.0(7)
[0535] C7 2143(2) 3951(3) 6695(2) 22.3(6)
[0536] C8 2360(2) 5561(3) 7044.9(19) 21.5(6)
[0537] S9 1518(2) 6003(3) 7546.9(19) 24.8(7)
[0538] SY 2058(2) 6185(3) 8596(2) 24.5(7)
[0539] SP 3229(2) 5853(4) 8757.3(19) 25.7(7)
[0540] C12 1575(2) 7519(3) 8001(2) 29.2(7)
[0541] C13 4278(2) 5518(3) 7527(2) 23.0(6)
[0542] C14 5316(2) 5558(4) 8326(2) 25.1(7)
[0543] C15 5895(2) 4033(3) 8479(2) 26.0(7)
[0544] S16 6302(2) 7871(4) 8737(2) 28.5(7)
[0545] S17 7021(3) 9001(4) 8428(2) 33.4(8)
[0546] S18 5121(3) 2848(4) 8650(2) 38.6(8)
[0547] S19 6323(2) 3586(4) 7639(2) 32.8(8)
[0548] S20 6826(3) 4168(4) 9386(2) 39.0(9)
[0549] S21 521(3) 8022(4) 8153(2) 47.4(10)
[0550] S22 2247(3) 8747(4) 7765(2) 41.5(9)
[0551] C23 33(3) 2579(4) 4897(2) 32.5(8) Atom Ueq
[0552] O1S 983(2) 5370(3) 3929.0(16) 47.9(6)
[0553] O2S 1277.8(19) 7143(3) 2951.7(17) 52.4(7)
[0554] CIS 1582(3) 6216(4) 3696(2) 37.0(8)
[0555] C2S 2734(3) 6341(6) 4195(3) 60.8(13)
[0556] C3S 154(3) 7077(5) 2402(3) 56.1(11)
[0557] C4S 51(4) 7437(6) 1404(3) 82.1(17)
[0558] C5S -1119(4) 7290(6) 831(3) 86.0(17)
[0559] C6S 735(9) 7070(20) 898(9) 82(2)
[0560] C7S 543(5) 8810(9) 1199(5) 82(2)
[0561] Single crystal X-ray diffraction data made it possible to accurately determine such characteristics of the crystal of tetrahydrofuran solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), such as: syngony, space group and cell parameters (Table 19), as well as fractional coordinates of atoms, equivalent thermal parameters (Table 20) and the arrangement of molecules in the unit cell (Fig. 3.5). The analysis was carried out at a temperature of 140 K, which corresponds to - 133.15 °C.
[0562] Table 19. Unit cell parameters of the crystalline form of tetrahydrofuran solvate of ( 1 R,2S,5S)-N-[( 1 S)- 1 -cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0563] *- where each of the parameters represents the length of one of the edges a, b or c.
[0564] **- where each of the parameters represents one of the angles between the edges a, 0 or y.
[0565] Table 20. Fractional coordinates of atoms and equivalent thermal parameters of the unit cell of U eq tetrahydrofuran solvate (!R,2S,5S)-N-[(l S)-l-UHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6- dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1 : 1).
[0566] Atom Ueq
[0567] F1 -971(5) 5980(3) 6275(2) 77.3(16)
[0568] F2 666(6) 5016(3) 6521(2) 76.0(16)
[0569] F3 -710(6) 4726(3) 5825(2) 79.2(17)
[0570] 01 7163(6) 1494(3) 4097(2) 63.6(18)
[0571] 02 6288(6) 5743(3) 3749(2) 54.4(16)
[0572] OZ 3966(5) 4469(3) 4647.0(19) 41.8(14)
[0573] 04 785(7) 6644(4) 5517(3) 92(2)
[0574] N1 8267(8) 2200(4) 4832(3) 55(2)
[0575] N2 5850(7) 4404(4) 3309(2) 38.6(16)
[0576] N3 3479(6) 5760(4) 4175(3) 34.8(15)
[0577] N4 2235(7) 5390(4) 5538(3) 41.8(17)
[0578] N5 8289(9) 4272(5) 2217(3) 82(3)
[0579] S1 7386(9) 3164(4) 4138(3) 44(2)
[0580] S2 8409(10) 3715(5) 4519(3) 53(2)
[0581] SZ 8563(12) 3126(4) 5057(3) 66(3)
[0582] S4 7580(10) 2190(5) 4352(4) 48(2)
[0583] S5 7664(9) 3216(4) 3506(3) 43(2)
[0584] S6 7362(9) 4172(5) 3260(3) 37.8(19)
[0585] C7 5428(9) 5181(5) 3574(3) 37(2)
[0586] C8 3783(8) 5314(5) 3635(3) 36.2(19)
[0587] S9 3197(9) 5945(5) 3189(3) 43(2)
[0588] СЮ 2760(9) 6827(5) 3482(4) 48(2) Atom x in Z
[0589] SP 3067(9) 6745(4) 4103(3) 43(2)
[0590] S12 1618(9) 6201(5) 3216(3) 50(2)
[0591] C13 3634(8) 5302(5) 4656(3) 35.8(19)
[0592] C14 3423(8) 5803(5) 5213(3) 37.9(19)
[0593] C15 4851(8) 5867(4) 5574(3) 41(2)
[0594] C16 1078(10) 5874(5) 5677(3) 48(2)
[0595] C17 -1(10) 5392(5) 6079(4) 51(2)
[0596] Cl 8 4553(10) 6542(5) 6065(3) 69(3)
[0597] C19 5308(9) 4937(5) 5832(4) 55(2)
[0598] C20 6062(8) 6240(5) 5191(3) 52(2)
[0599] C21 531(9) 5686(5) 3560(4) 63(3)
[0600] C22 995(10) 6553(6) 2657(3) 75(3)
[0601] S23 7891(9) 4243(5) 2672(4) 49(2)
[0602] 01 SA 4070(30) 2985(13) 2970(7) 89(4)
[0603] C1SA 3570(30) 2679(14) 2434(8) 83(4)
[0604] C2SA 3030(40) 1699(15) 2576(8) 100(4)
[0605] C3SA 2450(30) 1797(15) 3184(8) 95(4)
[0606] C4SA 3520(30) 2478(17) 3448(8) 101(4)
[0607] 01 SB 3390(18) 3183(8) 3094(5) 89(4)
[0608] Cl SB 2920(20) 3244(9) 2528(6) 83(4)
[0609] C2SB 3210(30) 2363(9) 2247(6) 100(4)
[0610] C3SB 3320(30) 1664(9) 2727(6) 95(4)
[0611] C4SB 3350(30) 2230(9) 3243(6) 101(4)
[0612] The X-ray diffraction patterns of solvated forms of (lR,2S,5S)-N-[(lS)-l-IIHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1) in crystalline / amorphous forms were obtained using a diffractometer using monochromatic copper Ka radiation equipped with a position-sensitive detector at room temperature (20 - 25 °C). In Figs. 4.1-4.5 and Table 21-25 show the diffraction maxima and diffraction patterns of the solvates of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) in crystalline forms according to the present invention.
[0613] Table 21. Characteristics of the main diffraction maxima of the crystalline form of the ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1).
[0614] In the diffraction pattern of the crystalline form of the ethyl acetate solvate of (1R,2S,5S)- N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characteristic peaks were observed in the region of 20 angles (± 0.20°): 12.47, 18.98, 19.92 (Fig. 4.1).
[0615] Table 22. Characteristics of the main diffraction maxima of the crystalline form of propyl acetate solvate (lR,2S,5S)-N-[(l S)-l-UHaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0616] Angle 20 (± Interplanar Relative
[0617] 0.20°), ° distance (d), A intensity, %
[0618] 6.29 14.04 34.9
[0619] 7.08 12.47 15.9
[0620] 10.70 8.26 13.4
[0621] 11.62 7.56 16.8
[0622] 12.13 7.28 27.6
[0623] 12.59 7.02 37.4
[0624] 13.82 6.40 1 1.3
[0625] 14.18 6.24 21.1
[0626] 14.56 6.08 45.0
[0627] 16.02 5.53 37.1
[0628] 17.04 5.20 15.2
[0629] 17.29 5.13 15.7
[0630] 18.26 4.85 19.1
[0631] 18.97 4.69 100.0
[0632] 19.72 4.50 16.3 20.47 4.33 11.2
[0633] 20.76 4.27 9.1
[0634] 21.02 4.22 10.6
[0635] 21.47 4.14 18.0
[0636] 22.00 4.04 10.7
[0637] 23.52 3.78 13.7
[0638] 23.74 3.75 9.0
[0639] 25.57 3.48 10.1
[0640] 26.27 3.39 10.3
[0641] 27.21 3.27 9.1
[0642] In the diffraction pattern of the crystalline form of the propyl acetate solvate (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characteristic peaks were observed in the region of 20 angles (± 0.20°): 12.13, 12.59, 18.97 (Fig. 4.2).
[0643] Table 23. Characteristics of the main diffraction maxima of the crystalline form of the butyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-nHaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0644] The diffraction pattern of the crystalline form of butyl acetate solvate (1R,2S,5S)-
[0645] K-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-Dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) exhibited characteristic peaks in the region of 20° angles (± 0.20°): 12.46, 15.92, 21.20 (Fig. 4.3).
[0646] Table 24. Characteristics of the main diffraction maxima of the crystalline form of isobutyl acetate solvate (lR,2S,5S)-N-[(lS)-l-HHaHO-2-[(3S)- 2 -oxopyrrolidin-3 -yl]ethyl]-3- [(2S)-3 ,3 -dimethyl-2- [(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0647] In the diffraction pattern of the crystalline form of the isobutyl acetate solvate of (1 ,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1 : 1), characteristic peaks were observed in the region of 20 angles (± 0.20°): 11.99, 12.65, 19.05. (Fig. 4.4).
[0648] Table 25. Characteristics of the main diffraction maxima of the crystalline form of tetrahydrofuran solvate (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1)-
[0649] In the diffraction pattern of the crystalline form of tetrahydrofuran solvate (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characteristic peaks were observed in the region of 20 angles (± 0.20°): 15.85, 18.52, 20.00 (Fig. 4.5).
[0650] Example 3. Obtaining medicinal forms of new azabicyclohexane derivatives.
[0651] 3.1. Capsules
[0652] To obtain a solid medicinal product in the form of a capsule containing a compound characterized by Formula I or Formula II or Formula IV according to the present invention, in particular the ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), lactose monohydrate, microcrystalline cellulose, ethyl acetate solvate were loaded into a fluidized bed mixer (lR,2S,5S)-N-[(lS)-l-4HaHo-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), and part of sodium croscarmellose. The resulting mixture was stirred while heating. Then the mixture was moistened with a solution of hydroxypropyl cellulose and sodium lauryl sulfate. The stirring process was continued until the humectant was completely added. The resulting pharmaceutical composition was dried.To obtain a finished pharmaceutical composition for encapsulation, the second part of sodium croscarmellose was added to the resulting mixture while stirring. Then, the process of dusting with magnesium stearate and talc was carried out. The resulting pharmaceutical composition for encapsulation was dosed into gelatin capsules.
[0653] Table 26. Composition of capsules containing ethyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1).
[0654] 3.2. Film-coated tablets
[0655] In order to obtain a solid medicinal product in the form of a film-coated tablet containing a compound characterized by Formula I or Formula II or Formula IV according to the present invention, in particular ethyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1) as an active agent, lactose monohydrate, ethyl acetate solvate of (1R,2S,5S)-N- [(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), low-substituted hyprolose and colloidal silicon dioxide. The resulting mixture was stirred with a stirrer while heating, followed by the addition of a humectant. A solution of sorbitan laurate and copovidone VA 64 were used as a humectant.The mixing process was continued until the humectant was completely added.
[0656] The resulting pharmaceutical composition was granulated with subsequent drying of the granules. To obtain a finished pharmaceutical composition for tableting, the resulting granulate was mixed with sodium croscarmellose. The resulting pharmaceutical composition was powdered with sodium stearyl fumarate with subsequent tableting on a rotary tablet press. The resulting cores were film-coated.
[0657] Table 27. Composition of film-coated tablets containing ethyl acetate solvate of (1H,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1).
[0658] Similarly, dosage forms of other forms of azabicyclohexane derivatives according to the present invention were obtained.
[0659] In addition, the physicochemical and technological properties of the medicinal products were studied, including structural studies, in particular, using the X-ray phase analysis method, stability was studied, and the compressibility indices of the mixtures were analyzed. As a result of the studies, improved stability indices of the medicinal products and compressibility of the mixtures containing new forms of solvated forms of (lR,2S,5S)-N-[(lS)-l-IIHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide according to the present invention were observed, while maintaining optimal flowability indices. Moreover, phase transitions from one crystalline or amorphous form to another were not recorded in any of the obtained medicinal products.The structure of each compound and / or mixtures thereof according to the present invention, as well as the quantitative characteristics of the active agent in the medicinal product, remained unchanged, which was confirmed by comprehensive studies, including X-ray diffraction and HPLC.
[0660] Example 4. Study of the physicochemical properties of new solvated forms of azabicyclohexane derivatives.
[0661] 4.1. Study of solubility of new solvated forms of azabicyclohexane derivatives.
[0662] The study of the solubility of the new solvated forms of the azabicyclohexane derivatives of the present invention, obtained in Example 1, was carried out by means of successive experiments described in the methodology according to OFS.1.2.1.0005.15 “Solubility”.
[0663] Methyl tert-butyl ether solvate (1B,28,58)-H-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, obtained according to the method described in the prior art (Owen DR et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of CO VID- 19 / / Science. - 202 l. - T. 374. - No. 6575. - P. 1586-1593), was used as a comparison sample in the experiment.
[0664] Method for determination of solubility of solvates of (lR,2S,5S)-N-[(l S)-l-unaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide:
[0665] A measured amount of solvent - water for injection (1.0 ml each) was added to weighed portions of substances ground into fine powders (each of samples 1, 5, 6, 10, 12, 15, 18, 23, 24, 25, 26, 27 and the prototype) (1.0 g) and the mixture was continuously shaken for 10 min at (23 ± 2) °C. Particles of the substance were observed in each mixture. Therefore, the samples did not dissolve. Then, to weighed portions of substances ground into fine powders (each of samples 1, 5, 6, 10, 12,
[0666] 15, 18, 23, 24, 25, 26, 27 samples and the prototype) (100.0 mg) were added with 1.0 ml of solvent - water for injection, and dissolution was carried out as described above. Dissolution of each sample also did not occur.
[0667] Next, to the weighed amounts of substances ground into fine powders (each of 1, 5, 6, 10, 12,
[0668] 15, 18, 23, 24, 25, 26, 27 samples and prototype) (100.0 mg) were added to 2.0 ml of solvent - water for injection, and dissolution was carried out as described above. The samples did not dissolve.
[0669] Next, to the weighed amounts of substances ground into fine powders (each of 1, 5, 6, 10, 12,
[0670] 15, 18, 23, 24, 25, 26, 27 samples and the prototype) (100.0 mg) were added with 7.0 ml of solvent - water for injection, and dissolution was carried out as described above. Samples 5, 6, 10, 15, 18, 23, 24, 25, 26, 27 dissolved completely. Samples 1 and the prototype did not dissolve. Particles of the substance were recorded in the mixtures when observed in transmitted light.
[0671] Next, 10.0 ml of solvent (water for injection) were added to the weighed amounts of the prototype sample and sample 1 (100.0 mg) ground into fine powders, and dissolution was carried out as described above. Samples 1 and the prototype did not dissolve.
[0672] Next, 10.0 ml of solvent (water for injection) were added to the weighed amounts of the prototype sample and sample 1 (10.0 mg) ground into fine powders, and dissolution was carried out as described above. The prototype sample dissolved completely. Particles of the substance were recorded in the mixture of Sample 1 when observed in transmitted light.
[0673] Next, 100.0 ml of solvent (water for injection) was added to a weighed portion of sample 1 ground into a fine powder (10.0 mg), and dissolution was carried out as described above. Sample 1 dissolved completely.
[0674] As a result of the conducted studies, it was possible to establish the following solubility characteristics of solvates of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (Table 28).
[0675] Table 28. Results of the solubility study of new solvated forms of (1K,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in comparison with the prototype.
[0676] Similarly, studies were carried out to determine the solubility of the solvates of (1R,2S,5S)-N-{(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide; (1R,2S,5S)-N-{(1S)- 1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(chlorodifluoroacetyl)-L-phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide; (lR,2S,5S)-N-{(lS)-l-4HaHO-2-[(38)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[M-(trifluoroacetyl)- -seryl]-3-azabicyclo[3.1.0]hexane-2-carboxamide; (lR,2S,5S)-N-{(lS)-l-pHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3 - [M-(trifluoroacetyl)-phenylalanyl]-3 - azabicyclo[3.1.0]hexane-2-carboxamide; specific crystalline and amorphous forms or mixtures thereof of solvates of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide of the present invention (for example, but not limited to, the ethyl acetate or propyl acetate solvate), as well as mixtures of said crystalline and amorphous forms of the present invention with the art-known forms of ( ,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (crystalline or amorphous) at different contents of said components in the mixtures (up to 70 wt.% of the content of solvated forms ( ,28,58)-Ы-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention from the weight of the said two-component mixture).
[0677] Table 29. Characteristics of solubility of substances.
[0678] As a result of the studies, it can be concluded that the solubility of the new solvated forms of the azabicyclohexane derivatives of the present invention, including in specific crystalline or amorphous forms, significantly exceeds the solubility of the methyl tert-butyl ether solvate of (lR,2S,5S)-N-[(lS)-l-ijHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the prototype. Similar studies of the solvates of the azabicyclohexane derivatives obtained according to Example 1 of the present invention showed a statistically significant improvement in solubility compared to the prototype sample.
[0679] Also, within the framework of the present invention, other physicochemical and technological properties were additionally studied, for example, stability and hygroscopicity, of the solvated forms of the azabicyclohexane derivatives of the present invention, including crystalline and amorphous forms and mixtures thereof, including mixtures thereof with other crystalline or amorphous forms of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide known in the prior art.
[0680] The conducted studies allowed us to conclude that the solvates of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, including in crystalline and amorphous forms, according to the present invention, are not prone to destruction as a result of exposure to elevated temperature and humidity. In contrast, methyl tert-butyl ether solvate (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the prototype showed noticeable degradation under the influence of elevated temperature and humidity within the framework of the stability study experiment.Analysis of samples by methods that allow identification of qualitative, quantitative and phase compositions during the experiment made it possible to establish improved stability of the phase composition of solvates of (lR,2S,5S)-N-[(lS)-l-HHaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, including in crystalline, amorphous forms and mixtures thereof, according to the present invention, compared to the prototype.
[0681] These studies have shown improved stability of the compositions of the present invention compared to the prototype.
[0682] The results obtained in the study of the hygroscopicity of new forms of azabicyclohexane derivatives according to the present invention clearly demonstrated a noticeable increase in the mass of the prototype samples during storage in a climatic chamber, which confirmed its hygroscopicity, in contrast to the samples according to the present invention, including solvates of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (for example, ethyl acetate and propyl acetate), including in crystalline and amorphous forms, according to the present invention, mixtures thereof, as well as mixtures of the said forms of solvates (lR,2S,5S)-N-[(lS)-l-pHaHO-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide with the forms of (lR,2S,5S)-N-[(lS)-l-4HaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide known in the art.
[0683] These studies have shown improved hygroscopic properties of the said compositions according to the present invention compared to the prototype.
[0684] Reduced hygroscopicity is a great advantage of the said new azabicyclohexane derivatives of the present invention, as well as mixtures of the said solvate forms of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide of the present invention with the known in the art forms of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidine-3- yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide, in the production and storage of substances, as well as medicinal products.
[0685] Example 5. Study of the therapeutic activity of solvates of azabicyclohexane derivatives according to the present invention against coronavirus infection.
[0686] The antiviral activity of the solvates of the azabicyclohexane derivatives of the present invention against the SARS-CoV-2 viral infection in vitro was studied in a Vero E6 cell culture. The obtained ECso values (the value of 50% of the maximum effective concentration) were in the range from 1970.0±25 to 2700.0±30 nM (the EC50 values of methyl tert-butyl ether solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide according to the prototype were 4400±47 nM). The antiviral activity of the solvates of the azabicyclohexane derivatives of the present invention against the SARS-Cov-2 virus was also studied using a model of experimental infection in Syrian hamsters caused by the Delta strain of the SARS-Cov-2 coronavirus.
[0687] The modeling of viral infection in Syrian hamsters was performed on 170 individuals, randomly distributed into 17 groups of 10 individuals each. The experiment involved male Syrian hamsters (8-9 weeks) weighing approximately 70 g. The hamsters had free access to water and food and were housed in a standard animal housing system in a vivarium.
[0688] Before the study, all animals were weighed and examined to establish the absence of external damage, damage to the hair coat, signs of intoxication, and an oropharyngeal swab was taken from all animals to conduct PCR for the presence / absence of SARS-CoV2 coronavirus RNA (negative control during infection). SARS-Cov-2 infection was carried out intranasally with anesthesia of individuals once at a dose of 10 5 TCID50 in a volume of 50 µl.
[0689] The 1st group received the ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-UHaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide;
[0690] The 2nd group received butyl acetate solvate of (!R,2S,5S)-N-[(l S)-l-uHaiio-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0691] The 3rd group received tetrahydrofuran solvate of (lR,2S,5S)-N-[(lS)-l-pHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide;
[0692] The 4th group obtained isobutyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-pHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0693] The 5th group received the propyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0694] The 6th group received acetone solvate of (lR,2S,5S)-N-[(lS)-l-unano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide;
[0695] The 7th group received dimethylformamide solvate of (lR,2S,5S)-N-[(lS)-l-pnaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0696] The 8th group received dimethyl sulfoxide solvate of (lR,2S,5S)-N-[(lS)-l-pHaHO-2-[(3S)- 2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0697] The 9th group received the ethanol solvate of (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0698] The 10th group received hydrate of (28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0699] The 11th group obtained the diethyl ether solvate of (lR,2S,5S)-N-[(lS)-l-ijHaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0700] The 12th group received the ethanol solvate of (lR,2S,5S)-N-{(lS)-l-IIHAHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-E-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide;
[0701] The 13th group obtained tetrahydrofuran solvate of (1R,2S,5S)-N- {(IS)- 1 -cyano-2- [(3S)-2- oxopyrrolidin-3 -yl] ethyl} -6,6- dimethyl-3 - [H-(chlorodifluoroacetyl)- -phenylalanyl] -3 - azabicyclo[3.1.0]hexane-2-carboxamide;
[0702] The 14th group received ethyl acetate solvate (lR,2S,5S)-N-{(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[N-(trifluoroacetyl)-b-seryl]-3- azabicyclo[3.1.0]hexane-2-carboxamide;
[0703] The 15th group obtained the butyl acetate solvate of (lR,2S,5S)-N-{(lS)-l-4HaHo-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[-(trifluoroacetyl)--phenylalanyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0704] The said solvates of the azabicyclohexane derivatives of the present invention were prepared according to Example 1.
[0705] The 16th group obtained methyl tert-butyl ether solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, taken as a prototype, obtained according to the method described in the prior art (Owen DR et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 / / Science. - 2021, - T. 374. - No. 6575. - P. 1586-1593). Individuals of the 17th group received a placebo - a suspension of microcrystalline cellulose. The drugs were administered orally through a tube as a suspension twice a day at a dosage of 200 mg / kg per individual. The size of the tube and the diameter of the tube olive were selected based on the anatomical and physiological characteristics of the hamsters. The volume for the introduction of ready-made doses did not exceed the recommended volume for intragastric administration for this type of animal - 5 ml / kg. The first administration was 2 hours before infection. The experiment was conducted for 5 days.
[0706] To study the viral load on the experimental animals, on the second day of the experiment, the content of SARS-CoV-2 virus RNA was analyzed in the oropharyngeal swabs of the individuals. In all hamsters of groups 1-17, viral RNA was detected in the oropharyngeal swabs already on the 2nd day. These results confirm that all animals of groups 1-17 were infected with the Delta strain of the SARS-CoV-2 virus.
[0707] At the end of the experiment, the animals were subjected to one-stage decapitation in accordance with the requirements of the ethical committee, the lungs were collected and the virus titer in the lung tissue was assessed. For this purpose, the lung tissue was homogenized. To destroy the cells and increase the yield of the virus, the homogenate was frozen-thawed once, centrifuged. The supernatant was collected, filtered and used for introduction into plasma samples. The viral load in the collected samples was determined quantitatively by titration with endpoint indication in Vero E6 cells.
[0708] The measured values of lgTCIDso / ml averaged across groups are shown in Fig. 5 and Fig. 6.
[0709] In groups 1-5, 7-15, a reliable difference in the virus titer in the lungs was recorded compared to group 6 (p<0.05); in groups 1-5, 7-15, a reliable difference in the virus titer in the lungs was recorded compared to group 16 (p<0.05); in groups 1-16, a reliable difference in the virus titer in the lungs was recorded compared to group 17 (p<0.05).
[0710] The mortality rate of animals in the control and experimental groups was also monitored during the studies. Based on the results obtained, the mortality percentage (C) was calculated in each group using the formula:
[0711] C = M : N, where M is the number of animals that died in 5 days, N is the total number of infected individuals in the group.
[0712] The average life expectancy (ALS) of individuals during the experiment was also determined. When determining the ALS in each group, the number of hamsters that lived a certain number of days after infection until death and the number of surviving animals were taken into account. The maximum life expectancy of surviving animals was taken to be 5 days. The results of the studies are presented in Table 30.
[0713] Table 30. Results of mortality rate measurements in groups 1–17.
[0714] * - reliable difference in mortality rate from the control group (p<0.05)
[0715] Moreover, two of the six surviving individuals showed a weight loss of more than 10-15% on the 5th day.
[0716] Based on the results of the experiment, it can be concluded that the solvates of the azabicyclohexane derivatives according to the present invention exhibit antiviral activity.
[0717] Throughout the experiment, clinical observation of the animals was also carried out, which also included recording the body weight of the animals. Each animal within the group was marked. In accordance with the mark, each animal selected for the study was assigned an individual number. The animals were observed daily, noting any deviations in the general condition of each animal. The average body weight of the animals before the experiment did not differ between the groups. The body weight of the animals was measured daily during the clinical examination on a TB-type table scale. The data on changes in body weight relative to the initial weight on the day of infection were recorded. Based on the observations in the first three days, a relative decrease in the average weight of individuals by group was recorded within 5%.However, on the 3rd day, the weight loss in groups 1-5, 7-15 was significantly less than in groups 6, 16, 17, in relation to the initial weight of the animals (before the start of the experiment), which indicates that the intoxication developing after infection with the SARS-CoV-2 virus in individuals in groups 1-5, 7-15 was less pronounced.
[0718] The change in the weight of individuals in groups 1-5, 7-15 began to stabilize starting from the 4th day of the experiment, and on the fifth day the average weight of individuals in groups 1-5, 7-15 returned to the initial values. In groups 6, 16 on the fourth day, approximately 50-70% of animals continued to decrease their average body weight by up to 9-10%, which indicates intoxication of individuals. The weight of the remaining individuals in groups 6, 16 began to gradually stabilize. In group 17, which received a placebo, a decrease in the average body weight of individuals in the group by more than 10% was observed until the end of the experiment.
[0719] In hamsters of groups 1-17, the following were recorded on days 1-3 after infection: symptoms of intoxication; moderate inhibition of activity and response to stimuli; decreased motor activity, but without gait and coordination disorders; decreased muscle tone; tousled, unkempt fur, but without bald spots. Starting from day 4, in groups 1-5, 7-15, normalization of the animals' condition to the initial one (before infection) was observed, in contrast to groups 6, 16 and 17, in which decreased motor activity, decreased muscle tone, impaired motor activity, unkempt fur were noted on days 4-5, while severe intoxication was recorded in individuals of group 17. Histopathological studies of the lung tissue of hamsters from groups 1-17 were also carried out.
[0720] In group 17, which received a placebo, histopathological analysis of the lungs of two of ten individuals demonstrated pulmonary infiltration by macrophages and lymphocytes, thickening of the alveolar septum, and characteristic damage to the vascular system, focal hemorrhages. In addition, additional biochemical analysis showed increased expression of proinflammatory cytokines and chemokines in the lungs. Analysis of lung samples from the remaining individuals of group 17 showed moderate damage and areas of necrosis of the lung epithelium; minor foci of inflammation (mainly in the bronchioles and adjacent alveoli); intra-alveolar and perivascular edema; while thickening of the alveolar septum and small foci of hemorrhage were recorded. Infiltration of neutrophils, macrophages, and lymphocytes was also observed.Histopathological analysis of the lungs of hamsters from groups 1-5, 7-15 showed that the solvates of azabicyclohexane derivatives according to the present invention exhibit a pronounced protective function of the lung tissue from the negative impact of the virus. Histopathological studies of the lungs showed minor damage to the organ. Inflammatory foci affected less than 7-8% of the lung tissue, while the lung damage was mild, in some individuals, moderate. Infiltration of neutrophils and macrophages in the alveoli was not recorded.
[0721] In group 6, 16, in which individuals received therapy with acetone and methyl tert-butyl ether solvates of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the prototype, an improvement in the histopathological parameters of the lungs was noted, including a decrease in the foci of inflammation in the lungs compared to group 17, however, unlike groups 1-5, 7-15, in individuals, inflammatory cell infiltration, thickening of the alveolar septum and damage to the vascular system (approximately 20- 30% of lung tissue).
[0722] The presented research results clearly demonstrate the therapeutic significance of the solvates of azabicyclohexane derivatives according to the present invention, expressed in accelerated recovery of individuals infected with the SARS-CoV-2 virus with a minimal risk of complications, including complications to the lungs. Thus, the solvates of azabicyclohexane derivatives according to the present invention are promising active agents in the treatment of viral diseases, possessing protective properties in relation to the lungs.
[0723] Similar results of the effectiveness of the new forms of azabicyclohexane derivatives according to the present invention were obtained by administering the said forms in dosages from 5 to 500 mg / kg (when converted to humans - from 40 to 4000 mg) per individual under certain dosing regimens.
[0724] Also, before analyzing the activity of the compounds claimed in the present invention, the toxicological properties of the new forms of azabicyclohexane derivatives according to the present invention were studied. The studies were conducted with oral administration on healthy mature individuals of rats and rabbits of both sexes of the same age, quarantined for 10-14 days. The spread in the initial weights of the experimental individuals did not exceed ± 10% of the average weight in the group. The animals had free access to water and food, were placed in a standard system of keeping animals in a vivarium. The experiments were carried out in accordance with established ethical standards.During the experiment, the general condition of the animals, their behavioral characteristics, intensity and nature of motor activity, presence and nature of seizures, coordination of movements, skeletal muscle tone, response to tactile, pain, sound and light stimuli, frequency and depth of respiratory movements, heart rate, condition of the fur and skin, color of the mucous membranes, pupil size, tail position, amount and consistency of feces, frequency of urination and color of urine, food and water consumption, changes in body weight and other indicators were recorded.
[0725] The dosages of new forms of azabicyclohexane derivatives according to the present invention up to 1000 mg / kg / day per individual were studied. As a result of the studies, it was possible to establish a complete absence of visible manifestations of toxicological effects, intoxication and death of animals against the background of taking new forms of azabicyclohexane derivatives according to the present invention.
[0726] Similar studies of other solvates of azabicyclohexane derivatives obtained according to Example 1 of the present invention did not show statistically significant differences in the results of the study of therapeutic activity against SARS-CoV-2 (the therapeutic activity of other solvates of azabicyclohexane derivatives according to the present invention was comparable to the activity of the solvates of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention)).
[0727] Thus, the new forms of azabicyclohexane derivatives of the present invention demonstrate improved efficacy, including protection of lung tissue during viral infection, compared to the acetone and methyl tert-butyl ether solvates of (lR,2S,5S)-N-[(lS)-l-pnaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0728] The presented research results clearly demonstrate the therapeutic significance of the new forms of azabicyclohexane derivatives according to the present invention, which is expressed, among other things, in the accelerated recovery of individuals infected with the SARS-CoV-2 virus with a minimal risk of complications.
[0729] Also, within the framework of the present invention, the antiviral activity of specific forms (crystalline, amorphous and mixtures thereof) of solvates of (28,58)--[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide according to the present invention, including ethyl acetate and propyl acetate, against the SARS-CoV-2 viral infection was additionally studied.
[0730] The novel solvate forms of (1R,2S,5S)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide of the present invention demonstrated improved efficacy, including protection of lung tissue during viral infection, compared to the methyl tert-butyl ether solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.
[0731] The results of the studies clearly demonstrated the therapeutic significance of the crystalline and amorphous forms of the solvates of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide according to the present invention, their mixtures, as well as their mixtures with the crystalline or amorphous forms of (lR,2S,5S)-N-[(lS)-l-4HaHO-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (WO2021250648 (form 1, form 5)), which results in accelerated recovery of individuals infected with the SARS-CoV-2 virus with a minimal risk of complications, including those affecting the lungs.
[0732] Thus, the new forms of azabicyclohexane derivatives according to the present invention are promising active agents in the treatment of viral diseases, possessing protective properties in relation to the lungs.
Claims
Invention formula 1. A compound selected from the group comprising compounds characterized by formula II: formula II where X is selected from the group consisting of ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, Ri and R2 independently of one another are Ci-C7 alkyl, R3, R4, Rs independently of one another are chlorine or fluorine, Re is selected from the group consisting of Ci-Cs alkyl, including branched, Ci-Cs alkoxy, C3-C10 cycloalkyl, phenyl, aryl, a 4-10-membered heterocycle optionally condensed with a 4-10-membered heterocycle, C4-C10 cycloalkyl or aryl, wherein said heterocycle contains 1-5 heteroatoms selected from -N, -S and -O, wherein Re is optionally substituted with C1-C7 alkyl, halogen, hydroxy group, phenyl, benzyl, aryl, amino, oxo or cyano groups, t= 0.5-5.0, n= 1.0-3.
0.
2. The compound according to claim 1, wherein X is selected from the group consisting of ethyl acetate, butyl acetate, tetrahydrofuran, isobutyl acetate, ethanol, water, diethyl ether, dimethylformamide, dimethyl sulfoxide and propyl acetate, Ri and R2 independently of one another are Ci alkyl, R3, R4, Rs independently of one another are chlorine or fluorine, Re is selected from the group consisting of tert-butyl, isopropyl, hydroxymethyl, -CH2- Ph, wherein m = 0.5-3.0, n = 1.
0.
3. The compound according to claim 1, selected from the group consisting of ethyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, butyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, tetrahydrofuran solvate ( 1 R,2S,5 S)-N- [( 1 S)- 1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexane-2-carboxamide, isobutyl acetate solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, ethanol solvate (1K,28.58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3- [(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, (lR,2S,5S)-N-[(lS)-l-UHaHO-2-[(3S)-2-hydrate Oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, diethyl ether solvate (1C,28,58)-M-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2, 2, 2-trifluoroacetyl)amino]butanoyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, dimethylformamide solvate (1R,2S,5S)-N- [( 1 S)- 1 -cyano-2- [(38)-2-oxopyrrolidin-3-yl]ethyl] -3 -[(2S)-3 ,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, dimethyl sulfoxide solvate ( ,28,58)-N-[(18)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3- Azabicyclo[3.1.0]hexane-2-carboxamide and propyl acetate solvate (1R,2S,5S)-N-[(1S)-1-cyano-2-[(38)-2-oxopyrrolidin-3-yl]ethyl]-3-[(28)-3,3-dimethyl-2-[(2,2,2- trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide.
4. A crystalline form of the ethyl acetate solvate of (!R,2S,5S)-N-[(lS)-l-unaHO- 2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1), characterized in that it has peaks in the powder diffraction pattern at the following angles 20° (± 0.20°): 12.47, 18.06, 18.98, 19.92, 21.
43.
5. The crystalline form according to claim 4, characterized by the following values of the parameters of the unit crystallographic cell: 12.83 ± 1.92, 8.75 ± 1.31, 14.90 ± 2.24 A, where each of the parameters represents the length of one of the edges a, b or c.
6. The crystalline form according to claim 4, characterized by the following values of the parameters of the elementary crystallographic cell: 90.00°, 111.01 ± 16.65°, 90.00°, where each of the parameters represents one of the angles between the edges a, p or y.
7. The crystalline form according to claim 4, characterized by a volume of the elementary crystallographic cell equal to 1560.00 ± 390.00 A 3 .
8. A crystalline form of the propyl acetate solvate of (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized in that it has peaks in the powder diffraction pattern at the following angles 20° (± 0.20°): 11.62, 12.13, 12.59, 18.97, 19.
72.
9. The crystalline form according to claim 8, characterized by the following values of the parameters of the elementary crystallographic cell: 12.80 ± 1.92, 8.90 ± 1.34, 14.49 ± 2.17 A, where each of the parameters represents the length of one of the edges a, b or c.
10. The crystalline form according to claim 8, characterized by the following values of the parameters of the elementary crystallographic cell: 90.00°, 104.56 ± 15.68°, 90.00°, where each of the parameters represents one of the angles between the edges a, P or y.
11. The crystalline form according to claim 8, characterized by a volume of the unit crystallographic cell equal to 1598.30 ± 399.58 A 3 .
12. A crystalline form of the compound according to paragraphs 4, 8, characterized by monoclinic syngony.
13. The crystalline form according to paragraphs 4, 8, characterized by the space group of the unit crystallographic cell P2ь 14. The crystalline form according to paragraphs 4, 8, characterized by the number of molecules in the unit crystallographic cell Z equal to 2.
15. The crystalline form according to paragraphs 4-14, characterized in that the powder diffraction pattern was obtained using a diffractometer using monochromatic Ka-radiation of copper.
16. An amorphous form of the ethyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1,0]hexane-2-carboxamide (1:1), characterized by having a wide halo in the powder diffraction pattern in the region of angles 20, ° (± 2.00°): 6.00° - 28.00°.
17. An amorphous form according to claim 16, characterized in that it has a wide halo in the powder diffraction pattern in the region of angles 20° (± 2.00°): 14.00° - 26.00°.
18. Amorphous form of propyl acetate solvate of (lR,2S,5S)-N-[(lS)-l-4naHO-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1:1), characterized by the fact that it has a wide halo in the region of angles 20 on the powder diffraction pattern, 0 (± 2.00°): 6.00° - 28.00°.
19. The amorphous form according to claim 18, characterized in that it has a wide halo in the region of angles 20 on the powder diffraction pattern, 0 (± 2.00°): 7.00° - 26.00°.
20. A pharmaceutical composition for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing an effective amount of a compound according to claims 1-19 and at least one pharmaceutically acceptable excipient.
21. A medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases, containing an effective amount of a compound according to claims 1-19 and at least one pharmaceutically acceptable excipient.
22. A medicinal product according to claim 21, containing a compound according to claims 1-19 in an amount of 100 to 400 mg.
23. The medicinal product according to claim 21, characterized in that the pharmaceutically acceptable excipient is selected from the group consisting of formulators, stabilizers, solubilizers, humectants, lubricants, glidants, thickeners, sweeteners, fragrances, flavorings, prolonged delivery regulators, diluents, fillers, emulsifiers, preservatives, antioxidants, buffering agents, cryoprotectants, pH-regulating agents, substances for maintaining isotonicity, or correcting substances.
24. The medicinal product according to paragraph 21, characterized in that it is a solid medicinal product.
25. The medicinal product according to paragraph 24, characterized in that it is a tablet, capsule or powder.
26. Use of a pharmaceutical composition according to claim 20 for the production of a medicinal product for the treatment and / or prevention of viral diseases by blocking the activity of 3C-like viral proteases.
27. The use according to paragraph 26, characterized in that the viral diseases are caused by coronavirus.
28. The use according to paragraph 27, characterized in that the viral disease is caused by the SARS-CoV-2 virus.
Citation Information
Patent Citations
2-oxo-3-pyrrolidinyl propionitrile compound as well as pharmaceutical composition and application thereof
CN114426568A
Nano-amorphous form (RS)-3-(4-amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione (versions), a method for production thereof and use for treating immunological or oncological diseases
RU2723624C1
Nitrile-containing antiviral compounds
WO2021250648A1
Inhibitors of cysteine proteases and methods of use thereof
WO2021252644A1
Protease inhibitors as antivirals
WO2022256434A1
Cited By
Anti-viral compounds
US12630538B2
